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are undefined. We used a combination of mutant mouse models, morpholino gene suppression in the
zebrafish, and cell culture to determine the role of these two proteins in cardiovascular system. Our
experiments with ATOH8 reveal a direct interaction between ATOH8 and the cardiovascular transcription
factors FOG2 and GATA4. This interaction is required in vivo in the developing zebrafish heart, where
Atoh8 functions with Gata and Fog factors to promote proper cardiac looping. However, our genetic
studies in the mouse show that ATOH8 is not required for cardiovascular development and has a much
weaker genetic interaction with GATA4 in mammals. These results identify a novel interaction and role for
Atoh8 in the zebrafish heart and also definitively exclude a requirement for ATOH8 in mammalian
development. Our experiments with MEKK3 reveal a requirement for this protein in regulating endocardial
growth factors that promote myocardial growth. We show that MEKK3 interacts with CCM2L, an
endocardial protein known to regulate growth factor production in the endocardium in conjunction with
the transmembrane protein HEG. Deletion of MEKK3 in the endocardium leads to embryonic death
secondary to decreased myocardium, likely due to decreased myocardial proliferation. MEKK3 genetically
interacts with HEG in vivo, providing additional evidence for coordinated function between MEKK3 and the
HEG-CCM complex. These findings highlight a new role for MEKK3 in cardiovascular development and
begin to identify the molecular mechanism underlying endocardial growth factor support for myocardial
growth.
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ABSTRACT

FUNCTIONS OF ATOH8 AND MEKK3 IN CARDIOVASCULAR DEVELOPMENT

David R. Rawnsley
Mark L. Kahn

The transcription factor ATOH8 and the kinase MEKK3 are evolutionary conserved
proteins with known expression within the cardiovascular system. However, the roles of
these proteins in the developing heart are undefined. We used a combination of mutant
mouse models, morpholino gene suppression in the zebrafish, and cell culture to
determine the role of these two proteins in cardiovascular system. Our experiments with
ATOH8 reveal a direct interaction between ATOH8 and the cardiovascular transcription
factors FOG2 and GATA4. This interaction is required in vivo in the developing
zebrafish heart, where Atoh8 functions with Gata and Fog factors to promote proper
cardiac looping. However, our genetic studies in the mouse show that ATOH8 is not
required for cardiovascular development and has a much weaker genetic interaction with
GATA4 in mammals. These results identify a novel interaction and role for Atoh8 in the
zebrafish heart and also definitively exclude a requirement for ATOH8 in mammalian
development. Our experiments with MEKK3 reveal a requirement for this protein in
regulating endocardial growth factors that promote myocardial growth. We show that
MEKK3 interacts with CCM2L, an endocardial protein known to regulate growth factor
production in the endocardium in conjunction with the transmembrane protein HEG.
iv

Deletion of MEKK3 in the endocardium leads to embryonic death secondary to decreased
myocardium, likely due to decreased myocardial proliferation. MEKK3 genetically
interacts with HEG in vivo, providing additional evidence for coordinated function
between MEKK3 and the HEG-CCM complex. These findings highlight a new role for
MEKK3 in cardiovascular development and begin to identify the molecular mechanism
underlying endocardial growth factor support for myocardial growth.
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Chapter 1: Introduction

Summary
This chapter will present an introduction to the two projects discussed in this
dissertation: 1) my studies on interactions between ATOH8 and GATA4-FOG2 in
development, and 2) my studies on the regulation of the endocardial growth factors by
the MEKK3 and the HEG-CCM complex. As these two projects are unrelated, this
chapter will be separated into two parts. In the first half, I will discuss the prior studies
performed on the transcriptional factor ATOH8. I will then discuss the known functions
and interactions of GATA4 and FOG2, two interacting partners of ATOH8, in the heart
and the lungs. In the second half of this introduction I will discuss pro-growth signaling
from the endocardium to the myocardium and also reciprocal signaling from the
myocardium to the endocardium. I will briefly discuss cerebral cavernous malformations
(CCM) and the CCM complex that underlies this disorder. I will then discuss the
additional CCM complex proteins that our lab has identified and the role that these
proteins play in endocardial growth factor signaling.

Introduction: Atoh8
In vitro and in vivo studies of ATOH8 in vertebrates
The gene Atonal homolog 8 (Atoh8) encodes the protein ATOH8, a basic helixloop-helix (bHLH) transcription factor. bHLH factors are defined by the presence of a
basic-helix-loop-helix domain in which the basic region binds DNA and the helix-loophelix region mediates dimerization to a second bHLH protein (1). Within the hierarchy
1

of bHLH factors, Atoh8 is the sole mammalian member of the Net family (2). The
ATOH8 bHLH domain shares 43-57% identity on the amino acid level with the bHLH
domains of proteins in the Atonal, NeuroD, and Neurogenin families, and the bHLH
domain is highly conserved across vertebrate ATOH8 homologues (3). Unlike many
genes within the atonal superfamily that are encoded by a single exon, Atoh8 has a unique
three-exon gene structure that is conserved from zebrafish to mammals (4). The
conserved gene structure and conserved sequence of the bHLH domain suggest the
possibility of an evolutionary conserved role for Atoh8 in vertebrates.
Several studies have attempted to ascribe functions to ATOH8 through both in
vitro and in vivo approaches. The first in vitro study overexpressed ATOH8 by retroviral
infection in murine retinal explants, which resulted in a decrease in glial cells and an
increase in rod cells, suggesting that ATOH8 may regulate neuronal-glial fate
determination (3). In vitro studies of ATOH8 function in the pancreatic cell lines
indicate that ATOH8 can physically interact with other bHLH factors, such as
NEUROG3 and NEUROD1, and can function as a transcriptional repressor of pancreatic
genes, suggesting a potential role in pancreatic development (5). Studies of cultured
human endothelial cells detected an upregulation of the human orthologue ATOH8 in
response to fluid flow, suggesting that ATOH8 may function in the endothelial response
to shear stress (6). All of these studies have been limited by being in vitro rather than in
vivo approaches, and it remains unclear whether ATOH8 has any required in vivo activity
in neural, pancreatic, or endothelial development or function.
Two studies have attempted to determine the in vivo requirements for ATOH8. In
the zebrafish, morpholino gene suppression studies of Atoh8 were performed to
2

determine the requirement in the developing fish (7). Morphant embryos developed
severe body plan malformations and died between 24 and 72 hours post fertilization
(hpf). Morphant embryos were observed to have impaired somite development, with
decreased expression of myogenic genes such as myoD and myogenein. Morphant
embryos also had a decreased number of neuronal cells in the retina, a finding possibly
consistent of the role in neural development that had previously been ascribed to murine
Atoh8 in retinal explant studies (3).
A second group attempted to determine the role of Atoh8 in mammals by deriving
an Atoh8 mutant mouse (5). This allele has a 10 kb deleted region containing exon 1,
exon 2, and the intervening intron 1; exons 1 and 2 contain nearly all of the Atoh8 coding
sequence. Mice homozygous for this allele were found to be dead by E8.5 and reportedly
appeared to have arrested shortly after gastrulation. This early lethality has precluded the
use of these mice in studying the developmental or postnatal requirement for ATOH8,
and the role for this gene in mammals has remained ambiguous.

GATA4 and FOG2 in heart and lung development
The GATA transcription factor family regulates the development of multiple
organ systems in vertebrates. GATA factors are characterized by binding to the DNA
binding motif WGATAR and by structural conservation of two zinc fingers (8). Among
the six vertebrate GATA factors, GATA4, GATA5, and GATA6 regulate multiple steps
in the development of the vertebrate heart, as well as several reproductive and
endodermal tissues (9-11). Although these factors are partially redundant (12,13),
GATA4 has been identified as a critical factor in cardiovascular development. GATA4-/3

embryos develop cardia bifida and die by E9.5 (14,15), and both endothelial and
myocardial-specific Gata4 deletions exhibit lethal embryonic cardiac defects (16,17).
Gata4 heterozygosity is sufficient to cause cardiac defects on certain genetic background,
as shown by Gata4+/- mice that develop septal defects and ventricular hypoplasia when
bred into a C57BL/6 background (18,19). Familial congenital heart defects have also
been linked to GATA4 heterozygosity, demonstrating that conservation of GATA4’s
critical role in the heart extends to humans (19-21). The cardiac requirement for GATA4
also extends to the developing zebrafish heart. Although gata5 appears to the most
critical GATA factor in the zebrafish cardiogenesis (22), morpholino gene suppression of
Gata4 results in an unlooped heart tube (23), indicating that GATA4 has a conserved
requirement in heart development that extends from fish to mammals.
GATA4 does not operate in isolation in cardiac development and has been shown
to interact with other cardiac transcription factors (e.g. Tbx5 (20)). Among these
interactions, the best characterized is that between GATA4 and FOG2, a member of the
Friend-of-GATA (FOG) family of transcriptional regulators (24,25). FOG proteins are
unable to bind DNA and must instead bind GATA factors in order to regulate
transcription (26). GATA factors bind FOG proteins via a highly conserved sequence on
the N-terminal GATA zinc finger, and a Gata4 point mutation that disrupts this
interaction in vivo phenocopies the loss of FOG2 (26,27). Thus, the major developmental
role of FOG2 is dependent on binding to GATA4. Interactions with FOG factors have
been shown to exert both positive and negative effects on GATA transcriptional activity
that depend on the cellular context (24,28-30). FOG proteins play critical roles in heart
development in multiple vertebrate species. In the mouse, loss of FOG2 results in cardiac
4

defects and embryonic death (31-33). In the zebrafish, loss of Fog1, the Fog factor
expressed in the heart, results in a failure of heart looping (34). Like GATA4, mutations
in FOG2 have been linked to human congenital heart disease (35), making further study
of GATA-FOG function and identification of additional GATA-FOG interacting partners
an important goal for understanding human disease.
In addition to their roles in heart development, FOG2 and GATA4 have additional
roles in the developing lung. A forward genetic screen in mice identified a point
mutation in Fog2 that results in disrupted diaphragmatic development and pulmonary
hypoplasia that was particularly severe in the accessory and right medial lobes (36). This
pulmonary role for FOG2 has also been observed in human patients, where FOG2 point
mutations have been linked to neonatal death from pulmonary aplasia and congenital
diaphragmatic hernia (36). Given FOG2’s dependence on a GATA factor for
transcriptional function, subsequent studies in the lung attempted to identify the GATA
partners of FOG2. Examination of lungs from mice homozygous for either Gata4 or
Gata6 point mutant alleles that could not bind FOG2 revealed that the GATA4-FOG2
interaction was critical for proper lung development (37), whereas the GATA6-FOG2
interaction was not required. In line with this observation, Gata4 and Fog2 expression in
the pulmonary system is limited to the mesenchyme of the developing lung (36), whereas
Gata6 expression is much more extensive (18,38). These results suggest a specific role
for the GATA4-FOG2 complex in pulmonary mesenchyme development, although there
is no evidence regarding which targets GATA4 and FOG2 regulate in the mesenchyme or
what other interacting partners they may have in this tissue.

5

Conclusions and Outstanding Questions
ATOH8 is a transcription factor with a bHLH domain that is highly conserved
across vertebrate species. This sequence conservation suggests a conserved requirement
for ATOH8 in these species. Although several reports have attempted to ascribe
functions to ATOH8, these studies have been limited by the flaws of the current in vivo
loss-of-function models. The zebrafish morpholino experiments provide evidence for a
requirement for Atoh8 in muscle and retinal development. However, the severe structural
defects in these embryos may mask more subtle phenotypes, and using lower doses of the
morpholinos may identify additional requirements for Atoh8. In the mouse, the early
embryonic death of the reported mutant mouse at gastrulation prevents any definitive
determination of the required roles for Atoh8 in mammals. To further study Atoh8,
additional mutant mouse models are required, particularly conditional alleles that will
allow us to bypass early lethality and enable us to derive tissue-specific deletions to
determine where and when Atoh8 is acting.
In the case of GATA4 and FOG2, the role of these proteins has been extensively
studied in the heart. However, it remains unclear what controls FOG2 binding to
GATA4—when does GATA4 bind FOG2, and when it is independent of FOG2? One
possibility is that other transcription factors may modulate FOG2-GATA4 binding and
promote or inhibit formation of FOG2-GATA4 complexes at different sites throughout
the genome. It would therefore be interesting to identify transcription factors that are
capable of physically interacting with GATA4-FOG2 and also capable of functionally
interacting with these proteins in vivo.

6

Introduction: CCM, MEKK3, and Endocardial Growth Factors
Endocardial-myocardial signaling
The inner wall of the myocardium of the heart is lined by endocardium, a
specialized form of endothelium. In addition to performing the traditional roles of
endothelium, such as separating circulating blood cells from cardiomyocytes and
inhibiting inappropriate activation of coagulation, the endocardium also produces
multiple growth factors that promote cardiomyocyte survival, proliferation, and
maturation. Concurrently with these endocardial signals, the myocardium produces
signals promoting endocardial development, creating a signaling cross talk that is
necessary for the development of both cell types within the heart.
Previous studies have identified the protein neuregulin and FGF factors as critical
endocardial growth factors. Neuregulin is a member of the epidermal growth factor
(EGF) family; endocardial neuregulin activates the myocardial receptors ErbB2 and
ErbB4 to promote cardiomyocyte survival and proliferation, and ventricular trabeculation
(39,40). Null mutations of neuregulin or its receptors lead to reduced myocardial
proliferation, decreased ventricular trabeculation, and embryonic death by E10.5 (41-43).
Similar findings have been observed with endocardial fibroblast growth factors (FGF)
and their associated FGF receptors (FGFR) in the myocardium. FGF9, FGF16, and
FGF20 are expressed from the endocardium during cardiac development and activate the
receptors Fgfr1 and Fgfr2 in the myocardium (44). FGF9-/- and FGF16-/- embryos both
exhibit reduced myocardial proliferation (44,45); similar myocardial phenotypes are seen
in mice lacking Fgfr1 and Fgfr2 in cardiomyocytes (44). It is unknown, however, what
signals drive endocardial neuregulin and FGF production.
7

Reciprocal myocardial signals to the endocardium include vascular endothelial
growth factor (VEGF) and angiopoietin-1 (ANG1). Myocardial VEGF, while not
required for endocardium survival, promotes induction of endocardial cells into
endothelial cells to form coronary arteries (46). Mice lacking myocardial ANG1 have a
thin myocardium and fail to develop ventricular trabeculations (47). As ANG1 activates
receptors on the endocardium, this result suggests that ANG1 promotes production of
endocardial growth factors that then facilitate myocardial growth and development,
although it is unknown what pathways ANG1 would activate in the endocardial cell to
drive growth factor production.
While multiple endocardial-to-myocardial growth factor pathways have been
identified, little is known about what regulates these pathways within the endocardium.
Prior work in our lab has identified the HEG-CCM pathway as a novel regulator of
endocardial growth factor production.

CCM Signaling and Endocardial Growth Factors
Cerebral cavernous malformations (CCM) are vascular lesions that develop
within the vasculature of the central nervous system (CNS) and predispose patients to
hemorrhagic stroke and focal neurological deficits (48). CCM lesions can either occur
sporadically or occur as an inherited familial disorder. Patients with familial CCM
lesions are heterozygous for CCM1, CCM2, or CCM3. CCM lesions form when a loss of
heterozygosity occurs within the endothelium of the CNS (49-51); CCM lesions caused
by mutations in any of the three genes are clinically indistinguishable, indicating that
CCM1, CCM2, and CCM3 likely operate in a common pathway (48). In support of this
8

conclusion, biochemical studies have demonstrated that CCM1, CCM2, and CCM3 form
a complex where CCM1 binds CCM2, which then binds CCM3 (52). Mice deficient for
CCM1, CCM2, or CCM3 develop early lethal embryonic vascular defects (53-55),
indicating that these proteins have a role in cardiovascular development in addition to
their known role in CCM disease pathogenesis.
Previous work in our lab identified two additional components of the CCM
complex: Heart-of-glass (HEG) and cerebral cavernous malformation 2-like (CCM2L).
HEG is a transmembrane protein that can interact with the CCM complex by binding
CCM1 (52). Loss of the zebrafish homologue Heg has been reported to result in
defective myocardial growth (56), phenocopying the loss of CCM1 and CCM2 in the
zebrafish (57) and linking Heg to the CCM complex. In the mouse, loss of Heg results in
death in approximately half of animals in late embryogenesis or early postnatal life from
either hemorrhages within the pulmonary vasculature or from myocardial ruptures
secondary to local patches of thin myocardium (52). Our lab has also identified CCM2L,
a paralogue of CCM2 that retains CCM2’s ability to bind CCM1 but cannot interact with
CCM3 (58). Ccm2l-/- mice are viable without overt defects; however, Heg-/- Ccm2l-/double mutant mice are lethal by E10.5 from heart failure secondary to reduced
myocardial proliferation (58). Expression of CCM2L and HEG at this time point is
limited to the endocardium, indicating that the myocardial defects were due to a depletion
of endocardial growth factors. Levels of FGF16 mRNA, a critical endocardial-tomyocardial growth factor (45,59), were found to be reduced in Heg-/- Ccm2l-/- hearts,
indicating that endocardial HEG and CCM2L are required to generate FGF16 and
promote myocardial growth.
9

Conclusions and Outstanding Questions
The past studies on HEG have revealed a role for this endocardial protein in
regulating myocardial growth (52,56). This role has become much clearer with the recent
report of the Heg-/- Ccm2l-/- double mutant mouse that dies by E10.5 from heart failure
secondary to profound myocardial thinning (58). These mice have decreased FGF16
levels in their hearts, identifying the likely target of HEG and CCM2L and also
identifying the mechanism through which myocardial growth is stimulated.
The central outstanding question of this project is identifying the mechanism
through which HEG and CCM2L regulate growth factor production. HEG is localized to
the membrane due to its transmembrane domain, and CCM2L is mostly localized near the
membrane due to its interaction with CCM1 and CCM1’s interaction with HEG. As
neither of these proteins have transcriptional function, there is no mechanism through
which they could directly alter FGF16 transcription. We conclude that there must an
associated pathway, likely binding CCM2L, that is modulating FGF16 transcription.
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Chapter 2: ATOH8 regulates GATA4 and FOG2 during Vertebrate Development

The data in this Chapter have been published in the Journal of Biological Chemistry (60).

Summary
Atonal homolog 8 (Atoh8) is a bHLH transcription factor that is highly conserved
in vertebrates. Here we show that zebrafish atoh8 is required for heart tube looping and
swimbladder inflation, and that atoh8 specifically interacts with gata4 and zfpm1 (Fog1)
in these developing tissues. We used co-immunoprecipitation studies to show that
ATOH8 can form a physical complex with GATA4 and FOG2, suggesting a molecular
mechanism explaining the genetic interaction in the zebrafish. In contrast to the role of
atoh8 in the zebrafish, multiple Atoh8 mutant mouse mice models exhibit normal cardiac
development, indicating that the cardiac function of Atoh8 is not required in the mouse.
We showed there is increased early postnatal death in Gata4+/- Atoh8GFP/GFP mice,
suggesting that genetic interaction between Gata4 and Atoh8 is conserved into mice. We
were unable to detect structural or functional defect in the hearts or lungs of these mice,
however, preventing us from determining the cause of death or site of GATA4-ATOH8
interaction in these mice.

Introduction
The gene Atonal homolog 8 (Atoh8) encodes the protein ATOH8, a basic helixloop-helix (bHLH) transcription factor within the atonal superfamily. The sequence of
the ATOH8 bHLH domain is highly conserved across vertebrate ATOH8 homologues
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(3), and Atoh8 has a unique three-exon gene structure that is conserved from zebrafish to
mammals and that is unique among bHLH factors in the atonal superfamily(4). The
conserved gene structure and conserved sequence of the bHLH domain suggest the
possibility of an evolutionary conserved role for Atoh8 in vertebrates.
As we previously discussed in Chapter 1, limited in vitro and in vivo studies have
several potential functions for Atoh8. Morpholino knockdown of atoh8 in the zebrafish
was reported to lead to severe developmental malformations and early embryonic death,
in addition to specific defects in development of the somites and retina (7). The early
death and severe defects seen in the atoh8 morphant embryos may mask more subtle
defects in other aspects of zebrafish development; lower doses of morpholinos may
bypass these early phenotypes and allow us to analyze the role of atoh8 in later
embryonic stages.
In contrast to the zebrafish, the in vivo requirement for Atoh8 in mammals has
remained elusive. One group has reported creation of an Atoh8 mutant allele with a
deletion of exon1, intron 1, and exon 2 (hereafter referred to as the Atoh8Δex1-2 allele) (5).
Atoh8Δex1-2/Δex1-2 mice were reported to be lethal by E8.5 and to be arrested at gastrulation.
This early lethality precluded further use of these mice in studying the developmental or
postnatal requirement for ATOH8 in specific tissues.
Prior to the publication of the lethal Atoh8Δex1-2 mouse and prior to the start of my
thesis project, our lab attempted to create an Atoh8 mutant mouse. The coding sequence
of eGFP followed by a stop codon was inserted into the first exon, replacing the Nterminus of the Atoh8 sequence and creating the Atoh8GFP allele. Mice homozygous for
this allele were viable on a C57BL/6-129/Sv mixed background, but exhibited runting
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that developed by weaning and persisted into adulthood. When these mice were bred
onto a pure C57BL/6 background, approximately 50% of the Atoh8GFP/GFP mice died
between birth and weaning (data not shown). These results strongly contradicted the
phenotype of the Atoh8Δex1-2/Δex1-2 mouse, which was completely lethal prior to E8.5 (5).
We interpreted this discrepancy as likely being due to the degree of deletion in these two
alleles, with the Atoh8Δex1-2 allele deleting multiple exons and the Atoh8GFP allele deleting
only a portion of Atoh8 exon 1. Two different hypotheses appeared possible from this
result. First, the Atoh8Δex1-2 allele could be a complete Atoh8 null allele and the Atoh8GFP
allele could be a hypomorphic allele. In this interpretation, total loss of Atoh8 in
Atoh8Δex1-2/Δex1-2 mice leads to early embryonic lethality, whereas partial Atoh8 function in
Atoh8GFP/GFP mice leads to runting and strain-dependent partial postnatal lethality.
Alternatively, the Atoh8GFP/GFP could be a true Atoh8 null allele, and Atoh8Δex1-2/Δex1-2
mice could have an additional defect unrelated to loss of ATOH8 protein that resulted in
its early embryonic lethality.
We hypothesized that ATOH8 had conserved and required functions in vertebrate
development. In order to test this hypothesis, we took two separate approaches to
examine in vivo ATOH8 function. First, we used morpholinos to knockdown atoh8 in
zebrafish embryos to identify additional in vivo requirements for atoh8. Secondly, in
order to identity the functions of Atoh8 in mammals, we generated and characterized
additional Atoh8 mutant mice models to definitely resolve the discordant phenotypes
between Atoh8Δex1-2/Δex1-2 and Atoh8GFP/GFP mice and to determine the requirement for
Atoh8 in mammalian development.
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Results
atoh8 is required for zebrafish heart looping and swim bladder development
There is a high degree of conservation between the mouse gene Atoh8 and the
zebrafish homolog atoh8 (3), suggesting that there may be a conserved function for this
gene across vertebrate species. Knockdown of atoh8 by morpholino in the zebrafish has
previously been reported to result in severe developmental malformations in skeletal
muscle somites and in the retina and death by 72 hpf (7). We hypothesized that lower
morpholino doses would reveal additional developmental roles for atoh8. We used the
same translation-blocking morpholino, atoh8-MO1, as Yao et al and lowered the injected
dose to 2.5 ng per embryo. At this dose embryos did not develop the retinal and skeletal
muscle defects seen at higher doses and greater than 90% of embryos survived beyond 72
hpf. Approximately 75% of embryos injected with atoh8-MO1 at a 2.5 ng dose
developed an unlooped heart tube and pericardial edema by 72 hpf (Figure 2.1.A-F). We
attempted to rescue this phenotype with atoh8 cRNA injection, but we were unable to
rescue due to toxicity of the cRNA by 72 hpf (data not shown). To confirm that this heart
phenotype was due to loss of atoh8, we injected two additional atoh8 morpholinos—one
targeting the splice donor site at the exon 1/intron 1 junction (atoh8-MO2) and an
additional translation-blocking morpholino targeting the 5’UTR (atoh8-MO3). Each
morpholino produced a similar heart tube looping defect (Figure 2.1.G-H). In contrast,
an atoh8-MO1 morpholino with five point mutations failed to induce a heart looping
defect (data not shown). To further test the specificity of the observed cardiac defects in
atoh8 knockdown zebrafish we lowered the doses of all three atoh8 morpholinos and
used them individually and in combination. At low doses single morpholinos induced
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heart looping defects in less than 10% of embryos; when used in combination greater
than 90% of embryos developed an unlooped heart (Figure 2.1.I). This synergy suggests
that the heart phenotype is due to knockdown of the same target gene by all three
morpholinos, indicating that this phenotype is due to specific loss of atoh8. These results
indicate that atoh8 is required for normal cardiac looping in zebrafish.
Morpholino knockdown of atoh8 also revealed that 95% of injected embryos
failed to develop an inflated swimbladder by 96 hpf (Figure 2.2.A-C). This swimbladder
phenotype was observed in embryos with the heart phenotype (Figure 2.2.B) as well as
embryos without the phenotype (Figure 2.2.C), indicating that the swimbladder defect is
highly penetrant and independent of the cardiac defect.

Atoh8 interacts specifically with Gata4 and Zfpm1 in the developing zebrafish heart
In order to identify candidate genes and pathways that interact with atoh8, we
looked for genes that exhibit similar heart and swimbladder defects in response to
morpholino knockdown. Knockdown of gata4 results in an unlooped heart, pericardial
edema, and an uninflated swimbladder (23). To determine whether a genetic interaction
exists between atoh8 and gata4, we injected zebrafish embryos with low dose gata4specific and atoh8-specific morpholinos individually and in combination. Embryos were
then scored to determine the penetrance of swimbladder and heart phenotypes to detect
genetic interaction between atoh8 and gata4 (61,62). Co-injection of atoh8 and gata4
morpholinos resulted in a synergistic increase in the penetrance of both the swimbladder
(Figure 2.3.A) and heart (Figure 2.3.B) phenotypes. These results suggest that atoh8
interacts with gata4 in the developing zebrafish swimbladder and heart.
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GATA factors are critical members in the transcriptional network controlling
vertebrate heart development (10). Within this transcriptional network, atoh8 may
interact specifically with gata4, or it may genetically interact with multiple cardiac
transcription factors. In order to determine the specificity of the atoh8-gata4 interaction,
we examined whether atoh8 exhibited genetic interaction with other transcription factors.
Heart looping defects in the zebrafish have been previously observed with morpholino
knockdown of mef2ca (61), tbx-5a (63), and zfpm1 (encoding Fog1) (34). Small additive
increases in the penetrance of the unlooped heart phenotype were observed when mef2ca
(Figure 2.3.C) or tbx-5a (Figure 2.3.D) morpholinos were injected in combination with
atoh8-MO1. In contrast, a larger synergistic increase was observed with co-injection of
zfpm1 and atoh8 morpholinos (Figure 2.3.E). These results suggest that atoh8
specifically interacts with gata4 and zfpm1 in the developing zebrafish heart.
gata4 and zfpm1 encode Gata4 and Fog1 proteins respectively. Previous studies
have revealed a physical interaction between mouse GATA4 and FOG2 (28), and
germline expression of a GATA4 point mutant that does not bind FOG2 phenocopies the
loss of FOG2 and leads to cardiovascular death in mice (27). Thus the interaction
between GATA and FOG factors is critical for heart development. To determine if a
similar genetic interaction exists between gata4 and zfpm1 in the zebrafish, we coinjected low doses of the gata4 and zfpm1 morpholinos. gata4-zfpm1 morpholino
combinations conferred an increased penetrance of the heart looping defect to a degree
similar to that observed with atoh8-gata4 and atoh8-zfpm1 morpholino combinations
(Figure 2.3.F), suggesting that Gata4 and Fog1 also interact in the developing zebrafish
heart
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Our results suggested that atoh8 might act in concert with both gata4 and zfpm1.
To further test this hypothesis, morpholino doses were lowered further and combinatorial
knockdown studies performed. At doses in which each individual morpholino induced
heart looping in <5% of embryos (Figure 2.3.G), injection of all three morpholinos
resulted in heart looping defects in approximately 90% of embryos (Figure 2.3.G). This
powerful synergy between the three transcription factors suggests a strong interaction
between atoh8, gata4, and zfpm1 in the developing zebrafish heart.

ATOH8 forms a biochemical complex with GATA4 and FOG2
The strong genetic interaction observed between atoh8, gata4 and zfpm1 in the
developing zebrafish suggested either that Atoh8 functions upstream or downstream of
the Gata-Fog complex in a common genetic pathway (i.e. an epistatic relationship) or that
these 3 transcription factors function together in a single complex (i.e. a biochemical
relationship). qPCR studies of fish embryos injected with atoh8 morpholinos failed to
reveal changes in the expression levels of either gata4 of zfpm1 and morpholino
knockdown of gata4 of zfpm1 did not alter atoh8 levels (data not shown), suggesting that
atoh8 does not interact with gata4 and fog1 epistatically. To assess a direct, physical
interaction between these transcription factors epitope-tagged mouse ATOH8, GATA4
and FOG2 proteins were co-expressed in HEK293T cells and a series of coimmunoprecipitation experiments performed. We were unable to immunopreciptiate
FLAG-ATOH8 and V5-GATA4 together (Figure 2.4.A). However, immunoprecipitation
of FLAG-ATOH8 was associated with co-immunoprecipitation of V5-FOG2 (Figure
2.4.A), and when all three proteins were co-expressed V5-GATA4 could be pulled down
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with both FLAG-ATOH8 and V5-FOG2 (Figure 2.4.B). Finally, co-expression of
FLAG-ATOH8, V5-FOG2 and V5-GATA4-V217G, a GATA4 point mutant that has
been shown to be unable to associate with FOG2 (27), confirmed that association of
GATA4 with ATOH8 is bridged by FOG2 (Figure 2.4.B). We attempted to confirm the
ATOH8-FOG2 interaction and assess a direct mechanism of interaction using GSTATOH8 and GST-FOG2 fusion protein binding assays, but we were unable to generate
the GST-FOG2 protein (perhaps due to the large size of FOG2) (data not shown). These
studies provided a biochemical explanation for the genetic interaction observed between
atoh8, gata4, and zfpm1 in the fish, and suggested that a similar relationship should exist
in the mouse.

atoh8 is weakly expressed in the zebrafish heart tube
Our co-immunopreciptiation experiments suggested that physical interaction
underlies the genetic interaction observed between atoh8, gata4 and zfpm1. Based on
this finding, we hypothesized that atoh8 is expressed in the zebrafish heart tube with
gata4 and zfpm1. In situ hybridization revealed atoh8 expression throughout the embryo
at 13 hpf (Figure 2.5.A-B), 30 hpf (Figure 2.5.C-D) and 48 hpf (Figure 2.5.F), consistent
with a previous report of atoh8 expression (7). Weak atoh8 expression was observed in
the heart tube at 30 hpf (Fig. 5C-D), overlapping with the cardiac expression of gata4
(Figure 2.5.E) and with the reported expression of zfpm1 (34). This expression data is
consistent with our hypothesis that a physical complex between the proteins Atoh8,
Gata4, and Fog1 in the zebrafish, and suggests this could be the molecular mechanism
underlying the genetic interaction we observe in the developing zebrafish.
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Atoh8 is not required for survival in the mouse
In order to determine the requirement for ATOH8 in the mouse, previous
members of our lab had created and begun to characterize an Atoh8 mutant mouse. The
eGFP coding sequence followed by a stop codon was inserted into exon 1 to generate the
Atoh8GFP allele (Figure 2.6.A); approximately 50% of the coding region of exon 1 was
deleted in this allele. On a mixed genetic background, Atoh8GFP/GFP mice were reported
to be viable but runted; when backcrossed onto a C57BL/6 genetic background,
approximately half of Atoh8GFP/GFP mice were reported to die prior to weaning (data not
shown). This phenotype differed significantly from a published report of an Atoh8
mutant mouse from another lab (5). This group used recombination with a bacterial
artificial chromosome (BAC) targeting vector to delete a 10 kilobase region of Atoh8,
replacing exon 1, intron 1, and exon 2 with sequence for an eGFP-Cre fusion protein (the
Atoh8Δex1-2 allele). Mice homozygous for this Atoh8Δex1-2 allele were reported to be lethal
shortly after gastrulation, precluding use of these mice to determine the function of Atoh8
in cardiac development.
Due to the discrepant phenotypes between these Atoh8GFP and Atoh8Δex1-2 mutant
models, we hypothesized that the Atoh8GFP allele may be a hypomorphic allele with
residual function. In order to create a definitive deletion of exon 1 of Atoh8, we designed
a mutant allele deleting all of exon 1 of Atoh8 (Figure 2.7.A). The 5’ loxP site was
placed 617 base pairs upstream of the transcriptional start site; this position places the
loxP outside a conserved region of sequence upstream of the Atoh8 transcribed region
that we suspected contain conserved regulatory elements and the Atoh8 promoter. The 3’
loxP was placed in intron 1. Recombination between these sites deletes exon 1 and the
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putative Atoh8 promoter. Atoh8fl/fl mice were viable with no apparent defects.
Transgenic mice expressing CMV-Cre (64) were used to recombine the Atoh8fl allele in
the mouse germline cells and create the Atoh8Δex1 allele (Figure 2.7.A). Atoh8Δex1/Δex1
mice were viable at the expected Mendelian ratio at postnatal day 14 on a mixed genetic
background (Table 2.1) and did not display any overt phenotypes into adulthood.
Atoh8Δex1/Δex1 mice also failed to exhibit the runting previously reported Atoh8GFP/GFP
mice, suggesting that the previous characterization of the Atoh8GFP/GFP mouse was
incorrect. At this point, we attempted to reproduce the previous data showing postnatal
death in Atoh8GFP/GFP mice on a C57BL/6 background. We were unable to reproduce this
data, as Atoh8GFP/GFP mice were found at Mendelian ratios (Table 2.2) and exhibited no
overt phenotypes. In summary, two different mutant alleles of Atoh8 exon 1
(Atoh8Δex1/Δex1 and Atoh8GFP/GFP) do not affect viability and indicate that Atoh8 exon 1 is
not required for survival in the mouse.
Although our Atoh8Δex1 allele removed exon 1 and the putative promoter of Atoh8,
we were able to detect continued expression of Atoh8 exon 2 and 3 mRNA transcript in
Atoh8Δex1/Δex1 mice by RT-PCR, suggesting that alternative transcripts exist for Atoh8. In
order to characterize these transcripts, we performed 5’ Rapid Amplification of cDNA
Ends (5’RACE) on mRNA isolated from Atoh8Δex1/Δex1 mice (data not shown). Using
primers in Atoh8 exon 2, we identified an alternative exon in intron 1 that spliced into
exon 2 and 3. There were no open reading frames in this transcript, however, indicating
that this transcript could not encode any truncated ATOH8 protein.
Although we were unable to identify any open reading frames in our Atoh8Δex1/Δex1
mice, it is possible that our 5’RACE experiments failed to identify all alternative
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transcripts. We hypothesized that, in Atoh8Δex1/Δex1 mice, such transcripts could splice
into the intact exon 2 and possibly create an open reading frame and a partially functional
ATOH8-like protein. This hypothesis would potentially explain the difference in
phenotype between our Atoh8Δex1/Δex1 mouse and the previously published Atoh8Δex1-2/Δex1-2
mouse that lacks both exon 1 and exon 2. To test this hypothesis and definitively address
the role of Atoh8 exon 2, we replaced exon 2 with an IRES-LacZ gene trap cassette to
generate the Atoh8 LacZΔex2 allele (Figure 2.8.A). Atoh8 LacZΔex2/LacZΔex2 mice were viable
and present at the expected Mendelian ratio at postnatal day 14 (Table 2.3). These results
indicate that exon 2 of Atoh8 is not required for survival in the mouse. Since exons 1 and
2 encode virtually the entire coding sequence of Atoh8, these results indicate that the
ATOH8 protein is not required in the mouse for survival, and that the embryonic lethality
of Atoh8Δex1-2/Δex1-2 mice does not reflect a requirement for ATOH8 protein during mouse
development but instead may reflect loss or alteration of another region due to the use of
a BAC targeting construct.

Atoh8 expression is restricted to the atria, lung mesenchyme, and vascular smooth
muscle in the mouse
In order to identify possible functions for Atoh8 in the mouse, we determined the
expression pattern of Atoh8. Due to the cardiac phenotype we identified in the atoh8
morphant fish, we first focused on Atoh8 expression in the heart. Previous studies have
reported cardiac expression of Atoh8 (3,5,65), but these studies have not defined the
precise spatial or temporal expression pattern of Atoh8 within the heart. In order to
determine the expression pattern of Atoh8, we generated antibodies against an N-terminal
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fragment of the ATOH8 protein. These antibodies were able to detect ATOH8 when
overexpressed in cell culture but could not detect ATOH8 in mouse tissues using
immunohistochemical staining (data not shown), and we were unable to use them to
determine Atoh8 expression in vivo.
In lieu of an effective antibody, we used the Atoh8LacZ∆ex2 IRES-LacZ gene trap
allele as a reporter for Atoh8 expression. Whole mount X-gal staining of Atoh8LacZ∆ex2/+
embryos at embryonic day 9.5 (E9.5) revealed LacZ expression in the developing brain,
eye, somites, limb bud and branchial arches, while the heart was free of LacZ expression
(Figure 2.9.A). This pattern was largely maintained at E12.5, with persistent LacZ
expression in somites, brain, eye, and limb bud (Figure 2.9.B), but no expression in the
developing heart or liver was detected (Figure 2.9.C). To determine whether Atoh8 is
expressed in later stages of heart development, we performed whole mount X-gal staining
on isolated Atoh8LacZ∆ex2/+ hearts (Figure 2.9.D). At E16.5, strong LacZ expression was
observed in both the aorta and pulmonary artery. There was weak staining of both the
left and right atria; the ventricles were negative except for the developing coronary
vessels. At postnatal day 1 (P1) strong expression in the aorta and pulmonary artery
persisted, with increased expression in the coronaries and atria, and no staining of the
ventricles. The vascular pattern in the great vessels and coronaries was maintained at
P14. However, the atrial pattern was altered, with continued right atrial expression but an
absence of expression in the left atrium. Whole mount X-gal staining of Atoh8LacZ∆ex2/+
organs also revealed strong expression throughout the lung at both E16.5 and P1 (Figure
2.9.E).
In order to determine which cells express Atoh8 in the heart, we next used
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immunohistochemistry to detect GFP expression from the Atoh8Δex1-2 nuclear GFP
reporter allele (5). As was seen with whole mount LacZ staining of Atoh8LacZΔex2/+ mice,
nuclear GFP expression was detected throughout the atrial myocardium at E16.5 (Figure
2.9.H-I). In contrast to whole mount LacZ staining, GFP expression in the atria could
also be detected at the earlier E12.5 time point (Figure 2.9.F-G), likely due to the higher
sensitivity of detection for this reporter. At both time points, the ventricles displayed
weaker expression than the atria (Fig. Figure 2.9.G, J). In the ventricles, nuclear GFP
expression was limited to the layers of cardiomyocytes in closest proximity to the
endocardium (Figure 2.9.J). These results indicate that cardiac expression of Atoh8 is
primarily limited to the atria.
We next used the Atoh8Δex1-2/+ GFP reporter allele to further define the Atoh8
expression pattern in the lung and vasculature. The GFP reporter showed strong
expression throughout the mesenchyme of the lung at E12.5 (Figure 2.9.K-L). In
contrast, the epithelium was completely devoid of GFP expression at E12.5 (Figure
2.9.L). This pattern of expression was preserved at E16.5, with strong mesenchymal
expression and no expression in the epithelium of either the proximal or distal airways
(Figure 2.9.M-N).
Atoh8Δex1-2/+ GFP expression was observed in the vascular smooth muscle of the
aorta and pulmonary artery (Figure 2.9.O-R), and in the smaller arteries of the lung
(Figure 2.9.T). The endothelium of these vessels was noticeably free of GFP expression
(Figure 2.9.Q), indicating that vascular Atoh8 expression is limited to the smooth muscle.
As in ventricular myocardium, GFP expression appeared to be strongest in the smooth
muscle cells directly underlying the endothelium (Figure 2.9.P-Q), suggesting that
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muscle cell Atoh8 expression may be regulated in some way by the endothelium. In
contrast to the arterial expression pattern, the pulmonary veins were largely free of GFP
expression (Figure 2.9.S). Thus studies of the Atoh8LacZ∆ex2 LacZ and Atoh8Δex1-2/+ GFP
reporter alleles are consistent and demonstrate that Atoh8 is specifically expressed in the
atria of the heart, lung mesenchyme, and arterial vascular smooth muscle. These findings
suggest that restricted gene expression in the mouse may explain the lack of an important
role for Atoh8 in mouse heart development.

Atoh8 interacts weakly with Gata4 in the mouse
Although our results indicated that there is not an absolute requirement for
ATOH8 in the mouse, our studies in zebrafish embryos and our biochemical studies
suggested that ATOH8 might be necessary for optimal GATA4 and/or FOG2 function in
mice. Loss of Gata4 or Zfpm2 (encoding FOG2) in the mouse leads to severe
cardiovascular defects and death at E9.5-10.5 and E13.5 respectively (14,15,31). To test
for genetic interaction between Atoh8 and Gata4 or Zfpm2 we generated Zfpm2+/Atoh8GFP/GFP and Gata4+/-Atoh8GFP/GFP animals. Zfpm2+/-Atoh8GFP/GFP animals were
viable and present at expected Mendelian ratios at both postnatal day 1 (P1) and postnatal
day 14 (P14) (Table 2.4). In contrast, a small decrease in the number of Gata4+/Atoh8GFP/GFP animals was observed at P1, and this deficit became more pronounced by
P14 (Table 2.5). Gata4+/-Atoh8GFP/GFP mice that survived past P14 were
indistinguishable from littermates and displayed no overt phenotypes, indicating that
death occurs in both the immediate neonatal (by P1) and early postnatal (P1-P14) periods.
The partial loss of Gata4+/-Atoh8GFP/GFP mice observed at P1 is consistent with
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either embryonic or neonatal death. To more precisely determine the time of death, we
examined embryos in late embryogenesis to determine viability of the Gata4+/Atoh8GFP/GFP animals in utero. In contrast to P1, there was no loss of Gata4+/Atoh8GFP/GFP embryos at embryonic day 17.5 (E17.5) relative to control littermates
(Table 2.6). These results indicate that loss of Gata4+/-Atoh8GFP/GFP mice occurs between
E17.5 and P1. These results reveal that although ATOH8 is not essential for mouse
development, genetic interaction between Gata4 and Atoh8 is conserved from zebrafish
to mammals.

Gata4+/-Atoh8GFP/GFP mice exhibit structurally normal hearts and lungs
We next sought to understand the small increase in mortality in Gata4+/Atoh8GFP/GFP mice. Gata4+/- heterozygotes have been reported to exhibit partial postnatal
lethality when backcrossed onto a C57/BL6 background (18,19). Although the cause of
death was not identified in these studies, a higher incidence of cardiovascular defects
(18,19) was identified in Gata4+/- animals compared to wild-type littermates. In order to
determine whether Gata4+/-Atoh8GFP/GFP mice die due to cardiac defects, we examined
animals in late embryogenesis for these defects. Gata4+/-Atoh8GFP/GFP mice did not
exhibit a decrease in cardiac fractional shortening at E17.5 relative to littermates (Figure
2.10.A), indicating that there is no myocardial or contractile defect in these animals.
Structural abnormalities were also not detected in Gata4+/-Atoh8GFP/GFP hearts by
histology (Figure 2.10.B-C). These results suggest that defective heart development is
not the cause of death in Gata4+/-Atoh8GFP/GFP mice. To further rule out a myocardial
cause of death in Gata4+/-Atoh8GFP/GFP mice, we generated Nkx2.5-Cre Gata4fl/+
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Atoh8GFP/GFP mice. In these mice Gata4 heterozygosity is limited to the Nkx2.5-lineage
cells, including the myocardium. There was no loss of Nkx2.5-Cre Gata4fl/+Atoh8GFP/GFP
mice at P1 (Table 2.7), confirming that the lethality seen in Gata4+/-Atoh8GFP/GFP mice is
not due to more subtle cardiac defects.
Our zebrafish studies identified the swimbladder as a site of gata4 and atoh8
interaction. The mammalian lung is the closest evolutionary equivalent to the
swimbladder; both organs share an origin from a common region of the endoderm (66)
and express similar surfactant proteins for inflation (67). In addition, Gata4+/heterozygotes on a C57/BL6 background have also been reported to exhibit an increase in
the pulmonary defects (18). These results suggested that the increased lethality observed
in Gata4+/-Atoh8GFP/GFP animals may be due to impaired lung development. We were
unable to detect gross structural abnormalities in Gata4+/-Atoh8GFP/GFP lungs (Figure
2.11.A-B) or a statistically significant change in lung mass (Figure 2.11.C) at E18.5.
There was also no change in the expression of the type II cell marker surfactant protein-C
(Sftpc) or the type I marker Aquaporin-5 (Aqp5) by quantitative RT-PCR (Figure 2.11.D)
at E18.5, suggesting that both type I and type II cells are present at normal numbers.
Although we could not identify morphologic defects in lung development, we next
examined the expression of molecular factors involved in mesenchymal-to-epithelial
signaling in Gata4+/-Atoh8GFP/GFP animals because pulmonary expression of Atoh8
(Figure 2.9.K-N) and Gata4 (18,37) is limited to the lung mesenchyme. Mesenchymal
expression of Wnt2, Fgf10, and Tbx4 has previously been shown to be required for proper
lung development (68-70). Expression of these factors was downregulated in both
Gata4+/- and Atoh8GFP/GFP lungs at E12.5 (Figure 2.11.E), although we did not observe an
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additional decrease in the expression of these factors in Gata4+/-Atoh8GFP/GFP compound
mutants. We also observed a decrease in the mRNA levels of the mesenchymal
transcription factor Twist1 in Atoh8GFP/GFP lungs, and Twist1 mRNA levels were further
decreased in Gata4+/-Atoh8GFP/GFP (Figure 2.11.E). These results suggest that Gata4 and
Atoh8 regulate gene expression in the developing lung mesenchyme. However, the lack
of any structural defects in the lung indicates that that the essential role for Atoh8 in
zebrafish swimbladder development is not conserved in the mammalian lung.

Discussion
Our studies revealed essential roles for Atoh8 in zebrafish cardiac and swim
bladder development that are performed in concert with Gata and Fog transcription
factors. Biochemical studies indicate that ATOH8, GATA, and FOG2 can form a
physical complex, suggesting that this molecular mechanism underlies the genetic
interactions observed in the developing zebrafish heart. However, our Atoh8 loss-offunction studies in the mouse indicate that Atoh8 is not required for survival in mammals
and that Atoh8 does not have a required role in mammalian cardiac development.
Expression analysis of Atoh8 in mice indicate that cardiovascular expression of Atoh8 is
primarily limited to atrial cardiomyocytes and vascular smooth muscle, possibly
explaining the lack of a requirement for Atoh8 in the developing heart. Our finding of
partial postnatal lethality in Gata4+/-Atoh8GFP/GFP demonstrates that a weak genetic
interaction between Gata4 and Atoh8 exists in mammals, but we were not able to link this
lethality to defects in either the heart or lungs.
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Previous studies of ATOH8 function in vivo have identified essential roles in both
zebrafish and mouse early embryogenesis (5,7). While our studies identify an additional
essential role in zebrafish development for cardiac looping, we find that neither the first
nor second exon of Atoh8 is required for mouse development or postnatal survival. Since
virtually the entire coding sequence of Atoh8 is contained within these two exons, these
findings demonstrate definitively that the ATOH8 protein is not required for mouse
development or survival. This result conflicts with a previous report of early embryonic
lethality in the Atoh8Δex1-2 mouse lacking both exon 1 and 2 and intervening intron 1 (5).
There exist several alternative explanations for the lethality seen in the Atoh8Δex1-2 mouse.
First, it is possible that removal of intron 1 in Atoh8Δex1-2 mice may have deleted a critical
non-coding element within this intron. Second, it is possible that this discrepancy could
reflect differences in strain background and the effect of modifier genes. This is unlikely
as both Atoh8Δex1-2 and Atoh8GFP mice were studied after being back-crossed more than 7
generations onto a pure C57Bl/6 background. Finally, it is possible that this difference
reflects disruption of a genetic element outside the Atoh8 locus in the Atoh8Δex1-2 mouse.
The Atoh8Δex1-2 mouse was created by gene targeting of ES cells using a bacterial
artificial chromosome (BAC) targeting vector, an approach that uses much longer
recombination arms than conventional gene targeting. With this approach recombination
can take place over a much larger area that, unlike gene targeting with conventional
vectors, cannot be fully assessed by PCR or Southern blot analysis of genomic DNA
following recombination. Thus it seems most likely that mutations outside the coding
region of Atoh8 are responsible for the embryonic lethality of Atoh8Δex1-2 mice.
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Our studies reveal a striking requirement for Atoh8 during early cardiac
development in the zebrafish, where it functions in close association with Gata4 and Fog1
to regulate cardiac looping (Figure 2.1 and 2.3). Zebrafish atoh8 displays a high degree
of sequence conservation with its murine orthologue Atoh8, particularly within the bHLH
domain (4), suggesting the possibility of a conserved role for Atoh8 in cardiac
development. This possibility is strengthened by the recent identification of an ultraconserved cardiac enhancer in the second intron of Atoh8 present in both fish and mice
(71), and by our finding that murine ATOH8 interacts with FOG2 and GATA4
biochemically. In contrast to Atoh8-deficient fish, however, mice lacking ATOH8 are
viable and do not display defects in heart development or function, even when put on a
Gata4+/- background to further stress the putative transcriptional mechanism. One
explanation for this species difference appears to lie in the highly specific and restricted
pattern of Atoh8 expression in the mouse heart. Using two different reporter alleles, we
detect Atoh8 predominantly within the atria during development and persistent expression
that becomes primarily restricted to the right atrium in mature animals. These results
suggest a shift in ATOH8 function from a broad role in regulating early cardiac
morphogenesis in the zebrafish to a more specific role in atrial development and/or
function in mammals, and perhaps one that is more important in the mature than
developing heart.
In addition to identifying an essential role for atoh8 in the development of the
zebrafish heart and swimbladder, our studies reveal strong and specific genetic
interaction between atoh8 and gata4 in the development of these tissues. This genetic
interaction is also weakly observed in mammals, as Gata4+/-Atoh8GFP/GFP mice exhibit a
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partially lethal phenotype. This phenotype is not due to a cardiac defect, as these animals
have functionally and structurally normal hearts. In addition, we were unable to
reproduce the lethality seen in Gata4+/-Atoh8GFP/GFP mice with myocardial-specific
deletion, further ruling out the heart as the cause of death. We could not determine the
basis for the compound lethality observed in mice, but the neonatal timing of this
lethality, our studies identifying the lung mesenchyme as a site of strong Atoh8 and
Gata4 expression, and the small changes in mesenchymal-to-epithelial signaling
observed in the developing lung of ATOH8-deficient embryos suggest that subtle defects
in lung function around the time of birth may be causal.
Our biochemical studies demonstrate that mouse ATOH8, FOG2 and GATA4 are
capable of forming a single protein complex in vitro, suggesting that ATOH8 may
regulate GATA and FOG function in mammals as well as fish. However, extensive
genetic studies to define such an interaction have very little requisite interaction during
development despite the important roles previously demonstrated for GATA4 and FOG2.
As suggested above, part of the explanation for this species difference appears to lie in
the restricted expression pattern of Atoh8 in the heart, the tissue in which GATA4 and
FOG2 play required roles during development. Another explanation for this difference
may lie in the expression and function of GATA and FOG in the mouse versus the
zebrafish. Previous studies using either hypomorphic Gata4 alleles or Gata4+/- animals
have revealed that partial loss of GATA4 is sufficient to confer a lethal phenotype
(18,19,72). In contrast, lethality in Fog2 heterozygotes has not been reported, suggesting
that larger reductions in FOG2 levels may be necessary to confer phenotypes in the
mouse. Since our biochemical studies implicate FOG as the bridge between ATOH8 and
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GATA, more insight into the role of ATOH8 may require a better understanding of the in
vivo roles of FOG and its mechanism of action.

Materials and Methods
Mice
We used the previously reported Gata4 null allele (14), Zfpm2 (Fog2) null allele
(31), Gata4fl floxed allele (73), CMV-Cre allele (64), Nkx2.5Cre allele (74), and Atoh8Δex12

allele (5). The Atoh8GFP, Atoh8Δex1, and Atoh8LacZΔex2 alleles were generated by creating

gene-targeting constructs by recombineering (75). SV/129 ES cells were targeted and
then screened by Southern blotting. We injected correctly targeted ES clones into
C57/BL6 blastocysts. Atoh8GFP/GFP mice were backcrossed onto a C57/BL6 background.
All other mouse experiments were done in mixed genetic backgrounds. The University
of Pennsylvania Institutional Animal Care and Use Committee approved all animal
protocols. The following genotyping primers were used:
Primers

Sequence

Atoh8GFP-WT-F
Atoh8GFP-GFP-R
Atoh8GFP-R
Atoh8flox-F
Atoh8flox-R
Atoh8Δex1-F
Atoh8Δex1-R
Atoh8Δex2-F
Atoh8Δex2-WT-R
Atoh8Δex2-LacZ-R
GATA4-F
GATA4-R
Fog2-WT-F
Fog2-Neo-F
Fog2-R

5’- GACACAGCCAGGGAATTCC -3’
5’- GCAGAAGAACGGCATCAAGG -3’
5’- GCAGAAGAACGGCATCAAGG -3’
5’- AAGCATGGGTGTTCTCCAGATTC -3’
5’- GGCTGGTCATTGTCATCCAACTG -3’
5’- AAGCATGGGTGTTCTCCAGATTC -3’
5’- AGAGCGGAAAGGTCGTGCTCT -3’
5’- TGGGAATAGCTGAGCAGGAT -3’
5’- CACACACTCGGAGAAGCTGA -3’
5’- ACCTGGTTGTCATGGAGGAG -3’
5’- CGAGACTAGTGAGACGTGCTA -3’
5’- ACTGGGTCTGCCATGTATCC -3’
5’- GCCAGATCTAATTCAAACAGCGTC -3’
5’- GCCTGCTCTTTACTGAAGGCTCTTT -3’
5’- CGTACCCAAGAAAGATTCTCTGCC -3’
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Cre-F
Cre-R

5’- GAACCTGATGGACATGTTCAGGGA -3’
5’- CAGAGTCATCCTTAGCGCCGTAAA -3’

Zebrafish morpholino studies
We used Tupfel long fin (TLF) strain zebrafish for all studies except for the
transgenic cardiac GFP studies. For the cardiac GFP studies, a previously described
transgenic cardiac reporter zebrafish line was used (76,77). Morpholino oligonucleotides
were obtained from Gene Tools and injected into one-cell-stage embryos at the indicated
doses. For all images, embryos were mounted in 2% methylcellulose, and bright field
and GFP images were acquired using an Olympus MVX10 microscope with an Olympus
DP72 camera. The University of Pennsylvania Institutional Animal Care and Use
Committee approved all animal protocols. Morpholino sequences are listed below:
Morpholino

Sequence

gata4

5’- TCCACAGGTGAGCGATTATTGCTCC -3’

zfpm1

5’- TCATGTCCCCCTTACCTCACTGGCA -3’

tbx5a

5’- CCTTCCTCTTCCAAAAGTACAGTCC -3’

mef2ca

5’- GAAAAGTGTCTTCACTGTCCGCCAT -3’

atoh8-MO1

5’- GTTTAGATGTGGGTTCTTCATTTCG -3’

atoh8-MO2

5’- CCGTGGGAATTTACCTGCTTTCTGA -3’

atoh8-MO3

5’- GATGTCCAGCCTGACTAATAAGTCC -3’

atoh8-MO1missense

5’- GTTTACATCTGCGTTGTTGATTTCG -3’

Control

5’- CCTCTTACCTCAGTTACAATTTATA -3’
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Zebrafish in situ hybridization
Tupfel long fin (TLF) strain zebrafish were used for all experiments. For the
gata4 and atoh8 probes, the coding region of each transcript was amplified from 48 hpf
zebrafish cDNA and cloned into pcDNA3. Probes were synthesized using a DIG RNA
labeling kit (Roche). In situ hybridization was performed as previous described (78).

Co-immunoprecipitation studies
cDNAs encoding GATA4, and FOG2 were cloned into pcDNA3.1 (Invitrogen);
V5 epitope tags were added during cloning. The GATA4-V217G point mutation was
introduced by site-directed mutagenesis. cDNA encoding ATOH8 was cloned into
p3XFLAG-CMV-7.1 (Sigma). Constructs were transiently transfected into HEK293T
cells using Fugene 6 (Roche). Nuclear extracts were isolated from transfected cells as
previously described (79). Immunoprecipitations were performed as previously
described (76). Flag-tagged Atoh8 was detected with HRP-conjugated anti-Flag-M2
antibody (1:1000, Sigma). V5-tagged proteins were detected with monoclonal mouse
anti-V5 antibody (1:5000, Invitrogen) and HRP-conjugated goat anti-mouse IgG antibody
(1:5,000 Jackson ImmunoResearch Laboratories Inc.)

GST fusion protein studies
cDNAs encoding ATOH8 and FOG2 were cloned into pGEX-4T-1 (GE
Healthcare Life Sciences) and transformed into BL21 E. coli. Transformed cells were
cultured at 37C to a density of A600=0.6 and induced with 0.1mM IPTG for 4 hours at
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30C. Proteins were purified from cell lysates by using a Bulk GST Purification Module
kit (GE Healthcare Life Sciences).

5’ rapid amplification of cDNA ends (RACE)
Total RNA was isolated from postnatal day 14 (P14) Atoh8 Δex1/Δex1 heart and liver
tissue using Trizol (Invitrogen). 5’ cDNA fragments were generated and amplified using
the SMARTer RACE cDNA Amplification Kit (Clontech). Following amplification,
fragments were separated by gel electrophoresis and purified (Qiagen). Isolated DNA
fragments were cloned into pCR2.1-TOPO by TOPO-TA cloning (Invitrogen). Single
clones were isolated and sequenced to identify the cDNA fragments.

Whole mount X-gal staining
Whole embryos or organs were dissected at the indicated ages. Tissues were
fixed and stained as previously described (80). Images were acquired using an Olympus
MVX10 microscope with an Olympus DP72 camera.

Histology and immunostaining
Mouse embryos at the indicated developmental stages were dissected, fixed in
paraformaldehyde, dehydrated, embedded in paraffin, and sectioned. We performed
immunostaining and hematoxylin-eosin staining. Histological techniques were
performed as previously described (81,82). For immunostaining, a goat polyclonal
antibody against GFP (1:250, Abcam) was used. Bright field and fluorescent images were
acquired using a Nikon Eclipse 80i microscope.
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Fetal echocardiography
Trans-uterine embryonic ultrasound was performed using a high-resolution Vevo
770 micro-ultrasound system (VisualSonics Inc.) as previously reported (83).

Gene expression studies
E12.5 lung buds and E18.5 lungs were dissected from embryonic mice. For
E12.5 lung buds, six lung buds were pooled together; for the E18.5 lungs, the right lung
was used. RNA was isolated from the tissue using Trizol (Invitrogen). 500ng of RNA
and 50ng random hexamer primers were then used to synthesize cDNA using the
SuperScript First-Strand Synthesis System (Invitogen). Quantitative RT-PCR was
performed using SYBR Green Master Mix (Applied Biosystems) on a 7900HT Fast RealTime PCR system (Applied Biosystems). RT-PCR primers are listed below:
Primer
Surfactant Protein C-Forward
Surfactant Protein C-Reverse
Aquaporin 5-Forward
Aquaporin 5-Reverse
Wnt2-Forward
Wnt2-Reverse
FGF10-Forward
FGF10-Reverse
Tbx4-Forward
Tbx4-Reverse
Twist1-Forward
Twist1-Reverse
GAPDH-Forward
GAPDH-Reverse

Sequence
5’- ACCCTGTGTGGAGAGCTACCA -3’
5’- TTTGCGGAGGGTCTTTCCT -3’
5’- ATGAACCCAGCCCGATCTTT -3’
5’- ACGATCGGTCCTACCCAGAAG -3’
5’- TCTTGAAACAAGAATGCAAGTGTCA -3’
5’- GAGATAGTCGCCTGTTTTCCTGAA -3’
5’- TGATGCAAAGGTTATCTGCACAT -3’
5’- GAGAGTTGCACTTCATACCAAATTTC -3’
5’- TGCCCCTCAACACCTTCCCA -3’
5’- TGGGGGTCACCTCACTGCAA -3’
5’- CGGACAAGCTGAGCAAGAT -3’
5′- GGACCTGGTACAGGAAGTCG -3′
5’- ATCACCATCTTCCAGGAGCGAG -3’
5’- GCCCTTCCACAATGCCAAAG -3’
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Statistics
P values in mouse genetic crosses were calculated using chi-squared tests. An
unpaired two-tailed Student’s t-test was used for all other p-values.
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Figure 2.1. Morpholino knockdown of atoh8 results in a failure of zebrafish heart
looping and pericardial edema.

Figure 2.1. Morpholino knockdown of atoh8 results in a failure of zebrafish heart
looping and pericardial edema. (A-F) One-cell zebrafish embryos were injected with
atoh8-MO1 morpholino (D-F) and examined at 72 hours post fertilization (hpf) in
comparison to uninjected controls (A-C). Transgenic fish expressing myocardial GFP
were used in C and F. (G-H) One-cell zebrafish embryos were injected with atoh8-MO2
(G) and atoh8-MO3 (H) and examined at 72 hpf. (I) Low doses of the three atoh8
morpholinos were injected independently and in combination into one-cell embryos and
then scored at 72 hpf for an unlooped heart tube. Graph in I shows the mean of three
injections; errors bars represent SEM.

37

Figure 2.2. Morpholino knockdown of atoh8 prevents swimbladder inflation.

Figure 2.2. Morpholino knockdown of atoh8 prevents swimbladder inflation. (AC) One cell zebrafish embryos were injected with atoh8-MO1. Swimbladder inflation
was scored at 96 hpf in injected embryos (B-C) versus wild-type (WT) embryos (A) at 96
hpf. Failure of swimbladder inflation was observed in morphant embryos with (B) and
without (C) the heart phenotype. SB=swimbladder, PE=pericardial edema. Swimbladder
location is outlined by dashed line.
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Figure 2.3. atoh8 specifically interacts with gata4 and zfpm1 in the zebrafish heart.
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Figure 2.3. atoh8 specifically interacts with gata4 and zfpm1 in the zebrafish heart.
(A) Low doses of atoh8-MO1 and gata4 MO were injected alone or in combination into
one-cell embryos and scored at 96hpf for failure of swimbladder inflation. (B-F) Low
doses of morpholinos were injected alone or in combination into one-cell embryos.
Embryos were scored at 72 hpf for the unlooped heart tube phenotype. The following
combinations were used: atoh8-MO1 + gata4 (B), atoh8-MO1 + mef2ca (C), atoh8-MO1
+ tbx5-a (D), atoh8-MO1 + zfpm1 (E), and gata4 + zfpm1 (F). (G) Doses for atoh8MO1, zfpm1, and gata4 morpholinos were lowered as indicated and injected individually
or in combination into one-cell embryos. Embryos were scored at 72 hpf for the
unlooped heart tube phenotype. For all experiments, control morpholino was used to
equalize amount of the total morpholino used in each injection. Graphs show the mean of
3 injections with >50 embryos per injection; errors bars represent SEM. * P<0.05, **
P<0.01, *** P<0.001
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Figure 2.4. ATOH8 physically interacts with FOG2 and indirectly with GATA4 via
FOG2.

Figure 2.4. ATOH8 physically interacts with FOG2 and indirectly with GATA4 via
FOG2. (A-B) FLAG-ATOH8, V5-GATA4-WT, V5-GATA4-V217G, and V5-FOG2
were transiently expressed in HEK293T cells in the indicated combinations,
immunoprecipitated with anti-FLAG antibody, and detected by Western blotting with
anti-Flag or anti-V5 antibodies as indicated. V5-GATA4-WT is wild-type GATA4 with
a V5 epitope tag. V5-GATA4-V217G is a GATA4 mutant with a V5 epitope tag and a
valine-to-glycine point mutation at residue 217 that abolishes FOG2-GATA4 interaction.
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Figure 2.5. atoh8 expression in the zebrafish.

Figure 2.5. atoh8 expression in the zebrafish. (A-B) atoh8 expression by in situ
hybridization at 13 hours post fertilization (hpf). Lateral (A) and dorsal (B) views are
shown. (C-E) In situ hybridization for atoh8 (C-D) and gata4 (E) at 30 hpf. Lateral (C)
and dorsal (D) views are shown for atoh8. Arrowheads in C and E indicate heart tubes.
(F) Expression of atoh8 at 48 hpf by in situ hybridization. Arrowhead in F indicates
heart.
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Figure 2.6. Targeting strategy for the Atoh8GFP allele.

Figure 2.6. Targeting strategy for the Atoh8GFP allele. The eGFP coding sequence
followed by a stop codon was inserted into exon 1. The PGK-Neo cassette was removed
in vivo by crossing these mice to a FLP-expressing mouse line to promote excision
between the FRT sites (blue circles). (B) Southern blot with NdeI digest to detect correct
targeting in embryonic stem cells is shown.
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Figure 2.7. Targeting strategy for the Atoh8fl and Atoh8Δex1 alleles.

Figure 2.7. Targeting strategy for the Atoh8fl and Atoh8Δex1 alleles. (A) LoxP sites
were inserted to flank exon 1 of the Atoh8 gene. The 5’ loxP was inserted upstream of a
conserved genomic region extending 517 bp 5’ of the transcriptional start site. Atoh8Δex1
allele was generated by Cre-mediated recombination of the Atoh8fl allele in the mouse
germline using CMV-Cre mouse line. Green triangles are LoxP sites; blue circles are
FRT sites. (B) Southern blot with SpeI digest to detect correct targeting in embryonic
stem cells. (C) Reverse-transcriptase PCR using primers in Atoh8 exons 1 and 3 to
confirm loss of exon 1 transcripts in Atoh8Δex1/Δex1 in the hearts of postnatal day 21 mice.
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Table 2.1. Survival of Atoh8∆ex1/∆ex1 mice at postnatal day 14.
Cross: Atoh8∆ex1/+ X Atoh8∆ex1/+
Genotype
Number Observed % Mendelian %
Atoh8+/+
43
30%
25%
∆ex1/+
Atoh8
70
48%
50%
Atoh8∆ex1/∆ex1
32
22%
25%
Total
145
P=0.39
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Table 2.2. Survival of Atoh8GFP/GFP mice at postnatal day 14.
Cross: Atoh8GFP/+ X Atoh8GFP/+
Genotype
Number Observed % Mendelian %
Atoh8+/+
28
34%
25%
GFP/+
Atoh8
34
40%
50%
Atoh8GFP/GFP
22
26%
25%
Total
84
P=0.14
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Figure 2.8. Targeting strategy for the Atoh8 LacZΔex2 allele.

Figure 2.8. Targeting strategy for the Atoh8 LacZΔex2 allele. (A) An IRES-LacZ gene
trap cassette was inserted in place of Atoh8 exon 2 to generate the Atoh8 LacZΔex2 allele.
The first three nucleotides of exon 2 were left in place to preserve the endogenous splice
acceptor site. Green triangles are LoxP sites; blue circles are FRT sites. (B) Southern
blot with NcoI digest was used to detect correct targeting in embryonic stem cells. (C)
Reverse-transcriptase PCR using primers in Atoh8 exons 1 and 3 to confirm loss of
transcripts in Atoh8LacZ∆ex2/LacZ∆ex2 in the hearts of postnatal day 21 mice.
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Table 2.3. Survival of Atoh8LacZ∆ex2/LacZ∆ex2/+ mutant mice at postnatal day 14.
Cross: Atoh8LacZ∆ex2/+ X Atoh8LacZ∆ex2/+
Genotype
Number Observed % Mendelian %
Atoh8+/+
17
26%
25%
LacZ∆ex2/+
Atoh8
29
45%
50%
Atoh8LacZ∆ex2/LacZ∆ex2
19
29%
25%
Total
65
P=0.64
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Figure 2.9. Atoh8 is expressed in the atria, lung mesenchyme, and vascular smooth
muscle.
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Figure 2.9. Atoh8 is expressed in the atria, lung mesenchyme, and vascular smooth
muscle. (A-C) Whole mount X-gal staining was performed on Atoh8LacZΔex2/+ embryos at
E9.5 (A) and E12.5 (B-C). C shows a magnified image of the boxed region in B with
forelimb removed. (D-E) Whole mount X-gal staining was performed at the indicated
stages on isolated Atoh8LacZΔex2/+ hearts (D) and Atoh8 LacZΔex2/+ lungs (E). (F-T) AntiGFP immunostaining of heart sections from Atoh8∆ex1-2/+ mice at E12.5 (F-G, K-L, O)
and E16.5 (H-J, M-N, P-T). Horseradish peroxidase staining was used in panels F-P and
R-T; FITC staining was used to panel Q. Arrowheads in Q indicate endothelial cells
lacking GFP expression. Scale is shown in each panel. H=heart, Liv=liver, Ao=aorta,
PA=pulmonary artery, RA=right atrium, RV=right ventricle, LA=left atrium, LV=left
ventricle, IVS=interventricular septum, ProxAir=proximal airway, DA= distal airway,
PV=pulmonary vein, Art=artery.
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Table 2.4. Survival of Zfpm2+/- Atoh8GFP/GFP mice at postnatal day 1 (P1) and
postnatal day 14 (P14).
Cross: Atoh8∆GFP/+ X Zfpm2+/- Atoh8GFP/+
Genotype
Number
Observed %
+/+
Atoh8
3
7%
Atoh8GFP/+
16
40%
Atoh8GFP/GFP
5
12%
Zfpm2+/- Atoh8+/+
2
5%
+/GFP/+
Zfpm2 Atoh8
11
27%
Zfpm2+/- Atoh8GFP/GFP
4
10%
Total
41

Age: P1
Mendelian %
12.5%
25%
12.5%
12.5%
25%
12.5%
P=0.27

Cross: Atoh8∆GFP/+ X Zfpm2+/- Atoh8GFP/+
Genotype
Number
Observed %
+/+
Atoh8
3
9%
Atoh8GFP/+
11
34%
Atoh8GFP/GFP
3
9%
Zfpm2+/- Atoh8+/+
2
6%
Zfpm2+/- Atoh8GFP/+
9
28%
Zfpm2+/- Atoh8GFP/GFP
4
12%
Total
32

Age: P14
Mendelian %
12.5%
25%
12.5%
12.5%
25%
12.5%
P=0.73

51

Table 2.5. Survival of Gata4+/- Atoh8GFP/GFP mice at postnatal day 1 (P1) and
postnatal day 14 (P14).
Cross: Atoh8∆GFP/+ X Gata4+/- Atoh8GFP/+
Genotype
Number
+/+
Atoh8
40
Atoh8GFP/+
66
GFP/GFP
Atoh8
25
Gata4+/- Atoh8+/+
24
+/GFP/+
Gata4 Atoh8
49
Gata4+/- Atoh8GFP/GFP
15
Total
219

Age: P1
Observed %
Mendelian %
18%
12.5%
30%
25%
11%
12.5%
11%
12.5%
22%
25%
7%
12.5%
P=0.0106

Cross: Atoh8∆GFP/+ X Gata4+/- Atoh8GFP/+
Genotype
Number
+/+
Atoh8
43
Atoh8GFP/+
69
GFP/GFP
Atoh8
23
Gata4+/- Atoh8+/+
21
Gata4+/- Atoh8GFP/+
35
+/GFP/GFP
Gata4 Atoh8
8
Total
199

Age: P14
Observed %
Mendelian %
22%
12.5%
35%
25%
12%
12.5%
11%
12.5%
18%
25%
4%
12.5%
P<0.0001
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Table 2.6. Viability of Gata4+/- Atoh8GFP/GFP embryos at embryonic day 17.5.
Cross: Atoh8∆GFP/+ X Gata4+/- Atoh8GFP/+
Genotype
Number
Observed %
Atoh8+/+
4
10%
GFP/+
Atoh8
11
27%
Atoh8GFP/GFP
2
5%
+/+/+
Gata4 Atoh8
8
19%
Gata4+/- Atoh8GFP/+
11
27%
+/GFP/GFP
Gata4 Atoh8
5
12%
Total
41
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Age: E17.5
Mendelian %
12.5%
25%
12.5%
12.5%
25%
12.5%
P=0.56

Figure 2.10. Gata4+/-Atoh8GFP/GFP embryonic hearts are functionally and structurally
normal.

Figure 2.10. Gata4+/-Atoh8GFP/GFP embryonic hearts are functionally and structurally
normal. (A) Ejection fraction was determined for Gata4+/-Atoh8GFP/GFP and littermates at
E17.5. N for each genotype is shown in panel. Graph shows mean of all samples of that
genotype; errors bars represent SEM. (B-C) Hematoxylin-eosin staining was performed
on E17.5 heart sections from control (B) and Gata4+/-Atoh8GFP/GFP (C) embryos. Scale is
shown in each panel.
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Table 2.7. Survival of Nkx2.5-Cre Gata4fl/+ Atoh8GFP/GFP embryos at postnatal day 1.
Cross: Nkx2.5-Cre Atoh8∆GFP/+ X Gata4fl/fl Atoh8GFP/GFP
Genotype
Number Observed %
Gata4fl/+ Atoh8GFP/+
7
25%
fl/+
GFP/GFP
Gata4 Atoh8
9
32%
Nkx2.5-Cre Gata4fl/+ Atoh8GFP/+
2
7%
fl/+
GFP/GFP
Nkx2.5-Cre Gata4 Atoh8
10
36%
Total
28
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Age: P1
Mendelian %
25%
25%
25%
25%
P=0.14

Figure 2.11. Gata4+/-Atoh8GFP/GFP lungs appear structurally normal but display
defects in mesenchymal-epithelial signaling.

Figure 2.11. Gata4+/-Atoh8GFP/GFP lungs appear structurally normal but display
defects in mesenchymal-epithelial signaling. (A-B) Hematoxylin-eosin staining was
performed on E18.5 lung sections from control (A) and Gata4+/-Atoh8GFP/GFP (B)
embryos. Scale is shown in each panel. (C) Lung/body weight ratios were measured at
E18.5 to compare lung growth between indicated genotypes. N=3-6 embryos per
genotype. (D) Surfactant Protein C and Aquaporin 5 expression in E18.5 lungs. N=3
lungs/genotype. (E) Wnt2, Fgf10, Tbx4, and Twist1 expression in E12.5 lung buds. N=6
lung buds/genotype. All graphs show the mean; errors bars represent SEM. * P<0.05
compared to WT, # P<0.05 compared to Atoh8GFP/GFP.

56

Chapter 3: Endocardial MEKK3 regulates myocardial growth

Summary
Previous work has identified the proteins Heart-of-glass (HEG) and cerebral
cavernous malformation 2-like (CCM2L) as endocardial factors that are required to
generate endocardial growth factors and promote myocardial growth (58). How HEG
and CCM2L regulate growth factor production has remained unclear. Here we identify
the MAPK cascade component MEKK3 as the likely link between HEG-CCM2L and
growth factor production. We show that MEKK3 interacts with CCM2L in coimmunoprecipitation experiments and that MEKK3 is required for CCM2L regulation of
FGF transcription in cell culture. We then establish that loss of endocardial MEKK3
leads to a lethal loss of myocardial growth, copying the phenotype seen Heg-/- Ccm2l-/mice and suggesting that MEKK3 is involved in the same pathway as HEG and CCM2L.
We then demonstrate genetic interaction between Heg and Map3k3 (encoding MEKK3),
further connecting MEKK3 to the HEG-CCM pathway in vivo.

Introduction
Cerebral cavernous malformations (CCM) are vascular lesions that develop
within the central nervous system that can lead to hemorrhagic stroke (48). CCM lesions
are linked to mutations in CCM1, CCM2, or CCM3 (49-51); biochemical studies have
demonstrated that these proteins form a complex where CCM1 binds CCM2, which then
binds CCM3 (52). Genetic studies of these genes in mouse models have reveal a
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requirement for these genes in early vascular development in addition to their role in
CCM pathogenesis.
In our lab’s previous work on CCM, we identified two additional components of
the CCM complex: Heart-of-glass (HEG) and cerebral cavernous malformation 2-like
(CCM2L). Neither of HEG nor CCM2L is involved in traditional CCM lesion formation.
Heg is a transmembrane protein that can interact with the CCM complex by binding
CCM1 (52). Loss of the zebrafish homologue Heg has been reported to result in
defective myocardial growth (56); in the mouse, loss of Heg results in death in half of the
animals by weaning from either pulmonary hemorrhage or from myocardial ruptures
secondary to local patches of thin myocardium (52). CCM2L is a paralogue of CCM2
can interact with CCM1 but cannot bind with CCM3 (58). Ccm2l-/- mice are viable;
however, Heg-/- Ccm2l-/- double mutant mice are lethal by E10.5 from heart failure
secondary to reduced myocardial proliferation (58). Heg-/- Ccm2l-/- embryos had normal
appearing endocardium but were found to have reduced levels of FGF16, an endocardialto-myocardial growth factor that has previously been linked to myocardial proliferation
(45,59).
Although our lab identified a requirement for HEG and CCM2L in regulating
endocardial FGF16 transcription, the mechanism for this regulation remains unclear.
HEG is embedded with the cell membrane and CCM2L is presumably in a complex with
CCM1 and HEG at the membrane, leading us to conclude that HEG and CCM2L must
facilitate some type of signaling pathway that regulates growth factor transcription. We
identified a likely candidate in MEKK3, a MAPK kinase kinase kinase. MEKK3 has
previously been shown to physically interact with CCM2 (84), suggesting it could also be
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a binding partner of CCM2L. Mice lacking MEKK3 are dead by E10.5 with widespread
vascular defects (85). These mice also exhibited myocardial thinning, although these
defects could be secondary to the vascular defects, precluding a clear understanding of
the role of MEKK3 in the heart.
We hypothesized that HEG-CCM2L control endocardial growth factor production
by regulating MEKK3. To test this hypothesis, we investigated whether MEKK3 could
physically interact with CCM2L and regulate CCM2L activation of FGF16 transcription.
We then investigated whether endocardial MEKK3 was required for myocardial growth
in the developing heart.

Results
MEKK3 can physically interact with either CCM2 or CCM2L
In order to identify signaling pathways that could connect the HEG-CCM
complex with transcription of FGF growth factors, we looked at known interacting
partners with CCM proteins. MEKK3 (encoded by the gene Map3k3) is a MAPK kinase
kinase kinase that has previously been reported to be required for vascular development
(85) and that has been reported to physically interact with CCM2 (84). Because of the
high homology between CCM2 and CCM2L, we hypothesized that MEKK3 could
physically interact with CCM2L. In order to test this hypothesis, we performed coimmunoprecipitation experiments to detect physical interaction between MEKK3 and
either CCM2 or CCM2L. We overexpressed HA-tagged MEKK3 (HA-MEKK3) with
either FLAG-tagged CCM2 (FLAG-CCM2) or FLAG-tagged CCM2L (FLAG-CCM2L)
in HEK293T cells and then performed immunoprecipitations with anti-FLAG antibodies.
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HA-MEKK3 co-immunoprecipitated with either FLAG-CCM2 or FLAG-CCM2L
(Figure 3.1), indicating that MEKK3 can physically interact with CCM2L in addition to
CCM2. These results are compatible with a mechanism where MEKK3 physically
interacts with CCM2L and facilitates signaling from the HEG-CCM1-CCM2L complex.

CCM2L increases FGF16 transcription via a MEKK3-dependent mechanism
Having demonstrated that MEKK3 could physically interact with CCM2L, we
next asked whether MEKK3 was required for CCM2L regulation of FGF transcription.
Our lab previously developed a cell culture model where adenoviral-mediated
overexpression of CCM2L in human microvascular endovascular cells (HMVEC) leads
to an upregulation of FGF16 transcription (58). In order to determine whether MEKK3 is
required for this regulation of FGF16 expression, we infected HMVECs with CCM2L
adenovirus or control LacZ adenovirus in the presence of MEKK3 siRNA or scramble
control siRNA. Adenoviral overexpression of CCM2L results in an approximately threefold increase in FGF16 expression (Figure 3.2). siRNA-mediated knockdown of
MEKK3 in HMVECs blocks this increase in FGF16 (Figure 3.2). This result indicates
that CCM2L regulates FGF16 via a MEKK3-dependent mechanism and supports our
hypothesis that MEKK3 functions in a signaling pathway between HEG-CCM2L and
FGF transcription.
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Nfatc1-Cre is limited to the developing endocardium and is not expressed in the
endothelium outside the heart
Having shown that MEKK3 is required for CCM2L regulation of FGF16
transcription in cell culture, we next asked whether MEKK3 is required in vivo in the
endocardium of the developing heart. MEKK3 is encoded by the gene Map3k3, and
Map3k3 mutants are reported to be lethal by embryonic day 10.5-11.0 with widespread
defects in cardiac and vascular development (85). Although conditional Map3k3 alleles
have been developed, the lack of a mouse Cre allele that specifically deletes in the
endocardium while sparing the rest of the endothelium has prevented a study of the
endocardial requirement for MEKK3. However, a group recently has published a report
of an endocardial-specific Cre allele, generated by insertion of an IRES-Cre cassette into
the 3’UTR of the Nfatc1 gene (hereafter referred to as Nfatc1Cre) (46). Within the
endothelial lineage, this allele is reported to delete within only the endocardium and in
the coronary vasculature endothelium that is later derived from endocardium, making this
allele an ideal tool for determining the endocardial requirement for MEKK3.
In order to validate the use of the Nfatc1Cre allele as an endocardial-specific Cre
deletor, we performed lineage analysis using the Nfatc1Cre allele and a previously
described R26R-EYFP reporter allele (86). Immunohistochemistry for EYFP and the
endothelial marker PECAM was used to determine the contribution of Nfatc1 to the
endocardium and endothelium in multiple vascular beds. At embryonic day 10.5 (E10.5),
Nfatc1Cre labels cells throughout the endocardium of the ventricle, atrium, and
atrioventricular cushions (Figure 3.3.A). EYFP reporter expression extends into the
proximal portion of the heart outflow tract (Figure 3.3.B), but it is excluded from the
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remainder of the aortic sac and branchial arch arteries (Figure 3.3.B-C), indicating that
Nfatc1Cre is limited to the endocardium and spares other endothelium at E10.5.
In order to determine the endothelial activity for Nfatc1Cre throughout
embryogenesis, we performed additional lineage tracing experiments on Nfatc1Cre R26REYFP neonates on postnatal day 1 (P1). EYFP reporter expression overlapped with
PECAM expression at P1 throughout the endocardium (Figure 3.3.D-G). EYFP reporter
expression was also seen in PECAM+ capillary and coronary artery endothelium in the
heart (Figure 3.3.D-G), a finding consistent with a previous report that endocardial cells
contribute to a significant portion of the cardiac vasculature (46). Nfatc1Cre lineage cells
also contributed to other endocardium-derived structures, including the cardiac valves
(Figure 3.3.H) and the endothelium of the proximal aorta (Figure 3.3.I).

We next

examined non-cardiac endothelium in P1 embryos to determine whether the Nfatc1Cre
allele was active in these cells. In contrast to the widespread expression of the EYFP
reporter in endocardial lineages, there is no EYFP expression in the endothelium of the
liver (Figure 3.3.J-K) or kidney (Figure 3.3.L-M) at P1, indicating that the Nfatc1Cre
allele is not active in endothelial cells other than the endocardium and the cardiac
vasculature. These results demonstrate that the expression of Nfatc1Cre allele is limited to
the endocardium and that this Cre allele can be used to create an endocardial-specific
deletion of MEKK3.

Endocardial MEKK3 is required for mouse survival and myocardial development
In order to determine whether MEKK3 is required in the endocardium, we
combined the Nfatc1Cre conditional allele with a previously reported Map3k3 (encoding
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MEKK3) floxed allele in which loxP sites flank exons 12-13, which encode several
subdomains of the MEKK3 kinase domain (87). Deletion of these exons has been shown
to result in a kinase-dead form of MEKK3 (87), and thus cells homozygous for this
mutation will be null for functional MEKK3. We were unable to find any Nfatc1Cre
Map3k3fl/- neonates when litters were genotyped at birth (Table 3.1), indicating that loss
of endocardial MEKK3 results in death during embryogenesis. Timed matings were then
performed to determine when Nfatc1Cre Map3k3fl/- embryos died. No viable Nfatc1Cre
Map3k3fl/- animals were found at E14.5 (Table 3.2), indicating that endocardial loss of
MEKK3 is lethal before this time point. At E10.5, Nfatc1Cre Map3k3fl/- embryos were
found at approximately 80% of the expected rate (Table 3.2), indicating that most
Nfatc1Cre Map3k3fl/- embryos are viable at this embryonic stage. By E11.5, the number of
Nfatc1Cre Map3k3fl/- embryos had decreased to less than 40% of the Mendelian prediction
(Table 3.2). Although additional crosses are need to determine the viability of these
embryos at E12.5 and E13.5, these results suggest that endocardial deletion of MEKK3
leads to embryonic loss beginning at E10.5-E11.5, with loss of all embryos by E14.5.
In order to determine the cause of death in Nfatc1Cre Map3k3fl/- embryos, we used
hematoxylin & eosin (H&E) staining to examine the structure of viable Nfatc1Cre
Map3k3fl/- embryos at E10.5 and E11.5. Nfatc1Cre Map3k3fl/- embryos had profound
myocardial thinning relative to littermate controls at E10.5 (Figure 3.4.A-D) and E11.5
(Figure 3.4.E-H), indicating that endocardial loss of MEKK3 has a deleterious effect on
myocardial development. In contrast, the endocardium was indistinguishable between
Nfatc1Cre Map3k3fl/- embryos and littermate controls (Figure 3.4.A-D, see arrowheads),
suggesting that endocardial development proceeds normally in these embryos. These
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results indicate that endocardial loss of MEKK3 results in lethal defects in myocardial
development. This result is nearly identical to the phenotype our lab previously observed
in Heg-/- Ccm2l-/- mouse (58). This is consistent with our hypothesis that MEKK3
functions downstream of HEG and CCM2L to promote endocardial production of growth
factors to facilitate myocardial growth, although further analysis of Nfatc1Cre Map3k3fl/embryos is needed to determine whether these animals have the same defects in
proliferation and endocardial FGF production as were seen in Heg-/- Ccm2l-/- embryos.

Endocardial CCM1 is required for survival in the embryonic mouse
Although the endothelial functions of CCM1, CCM2, and CCM3 in development
have been studied in mice with endothelial-specific (Tie2Cre) deletions of these genes, the
function of these proteins in the endocardium has remained unclear due to very early
embryonic death that occurs secondary to vascular defects (53-55). It would be
particularly interesting to examine embryos lacking endocardial CCM1 for defects
similar to Heg-/- Ccm2l-/- and Nfatc1Cre Map3k3fl/- embryos, due to the fact that we
suspect CCM1 forms a complex with HEG and CCM2L. Our Nfatc1Cre lineage trace and
our positive results with Nfatc1Cre Map3k3fl/- embryos suggest that the Nfatc1Cre allele
could be used to determine the endocardial requirement for CCM proteins. In order to
determine the function of CCM1 in the endocardium, we combined the Nfatc1Cre allele
with the Krit1fl allele (Krit1 encodes CCM1). Nfatc1Cre Krit1fl/fl mice are not found at
birth (Table 3.3), indicating that endocardial CCM1 is required for survival. We are now
undertaking timed matings to characterize the embryonic defects present in these mice
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and to determine whether endocardial CCM1 has a similar role in myocardial growth as
HEG, CCM2L, and MEKK3.

Heg and Map3k3 genetically interact in the endothelium and endocardium
In our previous studies of HEG and CCM proteins, our lab has utilized compound
genetic mutants to demonstrate genetic interaction between different members of this
complex. For example, in our studies of the Heg mutant mouse, our lab showed that Heg/-

CCM2+/- mice phenocopy the embryonic vascular defects of CCM2-/- mice (52),

implicating Heg in this developmental process. Such interactions provide evidence for
shared function in vivo. Because endocardial-specific deletion of MEKK3 displays a
similar phenotype to the Heg-/- Ccm2l-/- mouse, we hypothesized that Map3k3 (encoding
MEKK3) would exhibit genetic interaction with Ccm2l and Heg. To test this hypothesis,
we generated Ccm2l-/- Map3k3+/- and Heg-/- Map3k3+/-. Ccm2l-/- Map3k3+/- mice were
viable and had no overt phenotypes (data not shown). Viable Heg-/- Map3k3+/- mice,
however, were not found at birth (Table 3.4). Timed matings revealed that Heg-/Map3k3+/- die between E12.5 and E14.5 (Table 3.4). At E12.5 Heg-/- Map3k3+/- embryos
exhibited profound myocardial thinning relative to littermate controls (Figure 3.5),
although this phenotype was not completely penetrant. Viable Heg-/- Map3k3+/- animals
at E13.5 did not have a decrease in heart function at this time point (Figure 3.6). Given
that our genetic crosses indicate that all animals are dead by E14.5, this result suggests
that cardiac function is preserved in these animals until E13.5 and rapidly deteriorates by
E14.5.
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The embryonic lethality and myocardial thinning that we observe in Heg-/Map3k3+/- animals demonstrate that a genetic interaction exists between Heg and
Map3k3. We hypothesized that this interaction was taking place within the endothelium
and possibly specifically within the endocardium. In order to determine what cell type
underlies this interaction, we used Tie2Cre and Nfatc1Cre conditional alleles to respectively
generate Tie2Cre Heg-/- Map3k3fl/+and Nfatc1Cre Heg-/- Map3k3fl/+ mice. In these mice,
Heg deletion is global while Map3k3 heterozygosity is limited to all endothelium (with
Tie2Cre) or to only endocardium (with Nfatc1Cre). If the Heg-/- Map3k3+/- interaction we
observe is dependent on endocardial function of Map3k3, we would predict Nfatc1Cre
Heg-/- Map3k3fl/+ mice would copy the phenotype of Heg-/- Map3k3+/- mice; if it is
dependent on pan-endothelial function of Map3k3, we would predict Tie2Cre Heg-/Map3k3fl/+ mice would copy the phenotype of Heg-/- Map3k3+/- mice. In our matings
Tie2Cre Heg-/- Map3k3fl/+ mice were lethal at P1 and almost completely lethal at E14.5
(Table 3.5), mimicking the lethality we observe in Heg-/- Map3k3+/- mice. In contrast,
approximately half of the Nfatc1Cre Heg-/- Map3k3fl/+ mice were viable at E14.5 and at P1
(Table 3.6). These results suggest that the lethality we observed from genetic interaction
between Heg and Map3k3 is partially due to endocardial defects (as shown by the 50%
lethality in Nfatc1Cre Heg-/- Map3k3fl/+ mice) and partially due to other endothelial defects
(as shown by the increased lethality seen in Tie2Cre Heg-/- Map3k3fl/+ mice). We are
performing histology on these conditional mice to determine whether they have similar
cardiac pathology to Heg-/- Map3k3+/- mice.
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Discussion
Our studies of MEKK3 support our hypothesis that MEKK3 operates downstream
of HEG and CCM2L to facilitate growth factor production in the endocardium to support
myocardial growth. We demonstrate that MEKK3 can physically interact with CCM2L
and that MEKK3 is required in endothelial cell culture models for CCM2L-stimulated
FGF16 production. Our Nfatc1Cre Map3k3fl/- mouse studies demonstrate that endocardial
MEKK3 is required for myocardial growth, a finding consistent with a role for MEKK3
as an activator of endocardial growth factor production. Finally, we identify genetic
interaction between Heg and Map3k3, providing in vivo evidence connecting MEKK3 to
the HEG-CCM complex.
While previous studies of Map3k3-/- embryos had reported myocardial thinning
defects with loss of MEKK3 (85), it was unclear if this defect was due to a loss of
endocardial or myocardial MEKK3, or if it was a secondary consequence of global
vasculature defects. Our studies with the Nfatc1Cre Map3k3fl/- mice clearly identify an
endocardial requirement for MEKK3 in facilitating myocardial growth. Our lineage trace
experiments with the Nfatc1Cre R26R-EYFP mice demonstrate that Nfatc1Cre activity is
limited to the endocardium and indicate that the phenotypes in Nfatc1Cre Map3k3fl/- mice
are due to endocardial loss of MEKK3. In addition, the normal appearance of the
endocardium in Nfatc1Cre Map3k3fl/- suggests that the phenotype is due to a specific loss
of endocardial growth factors rather than a loss of endocardial cells. This phenotype—
loss of myocardium with normal endocardium—is a close copy of the Heg-/- Ccm2l-/phenotype, which supports our hypothesis that MEKK3 acts downstream of HEG and
CCM2L to facilitate growth factor production. Further studies are now needed to
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confirm that Nfatc1Cre Map3k3fl/- embryos have the same type of molecular defects as
Heg-/- Ccm2l-/- embryos. For example, we need to determine whether reduced FGF16
expression underlies the phenotype in Nfatc1Cre Map3k3fl/- embryos or whether changes
in other signals are responsible.
In our Heg-/- Map3k3+/- compound mutant embryos, we observed complete
embryonic lethality by E14.5, a much more severe phenotype than Heg-/- embryos, which
largely survive into the postnatal period (52). This lethality is a clear sign of genetic
interaction between Heg and Map3k3, serving as possible in vivo evidence linking
MEKK3 to the HEG-CCM complex. It is difficult, however, to determine how whether
Heg and Map3k3 are interacting in the endocardium or in other sites. We observe
myocardial thinning some Heg-/- Map3k3+/- embryos, suggesting that myocardial growth
may be impaired in these embryos, as it is in Nfatc1Cre Map3k3fl/- or Heg-/- Ccm2l-/embryos, although the phenotype is much less penetrant in Heg-/- Map3k3+/- embryos.
However, cardiac function was preserved in viable Heg-/- Map3k3+/- embryos at E13.5,
arguing against a cardiac cause of death in these animals. A similar discrepancy is
observed in Tie2Cre Heg-/- Map3k3fl/+versus Nfatc1Cre Heg-/- Map3k3fl/+ mice. Embryonic
death in endothelial (Tie2Cre) mutants is nearly completely penetrant, copying the
phenotype in Heg-/- Map3k3+/- embryos, whereas endocardial (Nfatc1Cre) mutants have a
50% reduction in death. The most likely explanation for this outcome is two separate
causes of death—an endocardial cause death and a separate vascular endothelial cause—
in Heg-/- Map3k3+/- embryos. In this model, a portion of the Heg-/- Map3k3+/- population
develops lethal myocardial thinning secondary to endocardial defects; this explains the
thin Heg-/- Map3k3+/- hearts and the partial lethality present in Nfatc1Cre Heg-/- Map3k3fl/+
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embryos. The rest of the Heg-/- Map3k3+/- population escapes this cardiac defect.
However, these survivors likely develops a second defect within the vasculature that
results in death at E14.5—this would explain the embryonic death we see in all Heg-/Map3k3+/- embryos and nearly all Tie2Cre Heg-/- Map3k3fl/+embryos. Further study is
needed to examine the histology of these conditional embryos to more completely
characterize the defects present in these animals.

Materials and Methods
Mice
We used the previously reported Map3k3 floxed allele (14), Heg mutant allele
(52), Tie2Cre allele (88), Nfatc1Cre allele (46) and R26R-EYFP allele (86). The Krit1fl is
unpublished and was provided by our collaborator Dean Li from the University of Utah.
All mouse experiments were done in mixed genetic backgrounds. The University of
Pennsylvania Institutional Animal Care and Use Committee approved all animal
protocols. The following genotyping primers were used:
Primers

Sequence

Map3k3-WT-F
Map3k3-FL-R
Map3k3-KO-R
Heg-WT-F
Heg-WT-R
Heg-LacZ-R
Krit1-F
Krit1-R
YFP-WT-F
YFP-WT-R
YFP-YFP-R
Cre-F
Cre-R

5’- CATTCTTTGCCAGGCAGTGG -3’
5’- CTCTATAGCAGGAGAAGAGC -3’
5’- AGACTCACTGGTCAGAGACC -3’
5’- CCTCCCGCGGCTCCCACAACTT -3’
5’- AGACTCTCACTCACCCGCGCTCA -3’
5’- GGCATCAGTCGGCTTGCGAGT -3’
5’- TGTCTCCATTCCCTCCTCCCTAC -3’
5’- AAACCAGCAGTCTCAACTAATCGG -3’
5’- AAAGTCGCTCTGAGTTGTTAT -3’
5’- GCGAAGAGTTTGTCCTCAACC -3’
5’- GGAGCGGGAGAAATGGATATG -3’
5’- GAACCTGATGGACATGTTCAGGGA -3’
5’- CAGAGTCATCCTTAGCGCCGTAAA -3’
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Co-immunoprecipitation studies
We used the previously described HA-MEKK3 expression vector (89) and
previously described FLAG-CCM2 and FLAG-CCM2L vectors (58) in our
immunoprecipitation experiments. Constructs were transiently transfected into
HEK293T cells using Fugene 6 (Roche). Cellular lysis and immunoprecipitations were
performed as previously described (76). FLAG-tagged CCM2 and CCM2L were
detected with HRP-conjugated anti-FLAG-M2 antibody (1:1000, Sigma). HA-tagged
proteins were detected with monoclonal mouse anti-HA antibody (1:10000, Covance)
and HRP-conjugated goat anti-mouse IgG antibody (1:5,000 Jackson ImmunoResearch
Laboratories Inc.).

Adenoviral Expression and siRNA studies in HMVECs
siRNA against human MEKK3 (Invitrogen) and scramble control siRNA
(Invitrogen) were transfected into human microvascular endothelial cells (HMVEC)
using RNAiMAX (Invitrogen). 24 hours after transfections, cells were infected with
adenovirus expressing HA-CCM2L or LacZ. Adenovirus dose was 2000gc/cell. RNA
was harvested from these cells 48 hours after adenoviral transfection using Trizol
(Invitrogen). 1000ng of RNA and 50ng random hexamer primers were then used to
synthesize cDNA using the SuperScript First-Strand Synthesis System (Invitogen).
Quantitative RT-PCR was performed using SYBR Green Master Mix (Applied
Biosystems) on a 7900HT Fast Real-Time PCR system (Applied Biosystems). RT-PCR
primers are listed below:
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Primer
hFGF16-Forward
hFGF16-Reverse

Sequence
5’- AGTGGACTCTGGCCTGTACCT -3’
5’- TTTGTTCAGGGCCACGTAATA -3’

Histology and immunostaining
Mouse embryos at the indicated developmental stages were dissected, fixed in
paraformaldehyde, dehydrated, embedded in paraffin, and sectioned. We performed
immunostaining and hematoxylin-eosin staining. Histological techniques were
performed as previously described (81,82). For immunostaining, a goat polyclonal
antibody against GFP (1:500, Abcam) was used to detect YFP, and a rat monoclonal
antibody against PECAM (1:500, BD Pharmingen). Bright field and fluorescent images
were acquired using a Nikon Eclipse 80i microscope.

Fetal echocardiography
Trans-uterine embryonic ultrasound was performed using a high-resolution Vevo
770 micro-ultrasound system (VisualSonics Inc.) as previously reported (83).

Statistics
P values in mouse genetic crosses were calculated using chi-squared tests. An
unpaired two-tailed Student’s t-test was used for all other p-values.
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Figure 3.1. MEKK3 physically interacts with CCM2 and CCM2L.

Figure 3.1. MEKK3 physically interacts with CCM2 and CCM2L. (A) HAMEKK3, Flag-CCM2, and Flag-CCM2L were transiently expressed in HEK293T in the
indicated combinations, immunoprecipitated with anti-Flag antibodies and detected by
Western blotting with the indicated antibodies.
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Figure 3.2. Overexpression of CCM2L upregulates FGF16 in human microvascular
endothelial cells via a MEKK3-dependent mechanism.

Figure 3.2. Overexpression of CCM2L upregulates FGF16 in human microvascular
endothelial cells via a MEKK3-dependent mechanism. (A) Adenoviral
overexpression of CCM2L increases FGF16 mRNA levels in human microvascular
endothelial cells (HMVEC). siRNA-mediated knockdown of MEKK3 blocks this
upregulation. HMVECs were transfected with indicated siRNA (MEKK3 or scramble
control) and infected with indicated adenoviruses 24 hours later. Cells were harvested 24
hours after adenoviral infection. Graph shows mean of 4 replicates +/- sem. *** P <
0.001.
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Figure 3.3. Nfatc1Cre deletes specifically in the endocardium and coronary
endothelium.
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Figure 3.3. Nfatc1Cre deletes specifically in the endocardium and coronary
endothelium. (A-C) Nfatc1Cre lineage tracing with the R26R-YFP reporter labels the
E10.5 endocardium while sparing the aorta and brachial arch arteries. (D-I) Nfatc1Cre
lineage cells contribute to the endocardium, cardiac valves, and the coronary endothelium
at P1. R26R-YFP reporter expression overlaps with PECAM expression in the
endocardium and coronary endothelium (D-G). YFP expression is also seen in
endocardium-derived structures such as the cardiac valves (H) and the proximal aortic
endothelium (I). (J-M) Nfatc1Cre lineage cells do not contribute to PECAM+ endothelial
cells in the liver (J-K) or kidney (L-M) vascular beds. K and M show higher
magnification images of J and L, respectively. Abbreviations: Atr=atrium,
AVC=atrioventricular cushion, Vent=common ventricle, Ao=aortic sac, BAA=branchial
arch artery, LV=left ventricle, RV=right ventricle, CA=coronary artery.
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Table 3.1. Survival of Nfatc1Cre/+ Map3k3fl/- mice at P1.
Cross: Nfatc1Cre/+ Map3k3+/- X Map3k3fl/fl
Genotype
Number
Observed % Mendelian %
Map3k3fl/+
14
25%
25%
fl/Map3k3
19
33%
25%
Cre/+
fl/+
Nfatc1
Map3k3
21
42%
25%
Nfatc1Cre/+ Map3k3fl/0
0%
25%
Total
54
P<0.001
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Table 3.2. Embryonic survival of Nfatc1Cre/+ Map3k3fl/- mice.
Cross: Nfatc1Cre/+ Map3k3+/- X Map3k3fl/fl
Age: E10.5
Genotype
Number
Observed % Mendelian %
fl/+
Map3k3
29
29%
25%
fl/Map3k3
29
29%
25%
Nfatc1Cre/+ Map3k3fl/+
23
23%
25%
Cre/+
fl/Nfatc1
Map3k3
19
19%
25%
Total
100
P=0.410
Genotype
Map3k3fl/+
Map3k3fl/Nfatc1Cre/+ Map3k3fl/+
Nfatc1Cre/+ Map3k3fl/Total

Age: E11.5
Number
Observed %
15
27%
23
42%
12
22%
5
9%
55

Mendelian %
25%
25%
25%
25%
P=0.007

Genotype
Map3k3fl/+
Map3k3fl/Nfatc1Cre/+ Map3k3fl/+
Nfatc1Cre/+ Map3k3fl/Total

Age: E14.5
Number
Observed %
16
31%
11
22%
24
47%
0
0%
51

Mendelian %
25%
25%
25%
25%
P<0.001
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Figure 3.4. Nfatc1Cre Map3k3fl/- embryos exhibit myocardial thinning.
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Figure 3.4. Nfatc1Cre Map3k3fl/- embryos exhibit myocardial thinning. (A-D)
Nfatc1Cre Map3k3fl/- embryos exhibit myocardial thinning relative to littermates at E10.5.
The endocardium (arrowheads in A-D) is intact and indistinguishable between Nfatc1Cre
Map3k3fl/- embryos and controls. B and D are higher magnification images of boxed
region in A and C, respectively. (E-H) Nfatc1Cre Map3k3fl/- embryos exhibit myocardial
thinning relative to littermates at E11.5. F and H are higher magnification images of
boxed region in E and G, respectively. Scale bars are 100µm in A, C, E, G, and 50µm in
B, D, F, H.
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Table 3.3. Survival of Nfatc1Cre/+ Krit1fl/fl mice at P1.
Cross: Nfatc1Cre/+ Krit1fl/+ X Krit1fl/fl
Genotype
Number
Observed %
Krit1fl/+
13
48%
fl/fl
Krit1
6
22%
Cre/+
fl/+
Nfatc1
Krit1
8
30%
Nfatc1Cre/+ Krit1fl/fl
0
0%
Total
27
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Mendelian %
25%
25%
25%
25%
P=0.005

Table 3.4. Survival of Heg-/- Map3k3+/- mice.

Age
E12.5
E13.5
E14.5
P1

Cross: Heg-/- X Heg+/- Map3k3+/Heg+/Heg-/Heg+/Heg-/+/Map3k3
Map3k3+/14
11
10
7
20
16
15
7
19
17
13
0
27
15
32
0

81

Total

P-value

42
58
49
74

0.50
0.10
<0.001
<0.001

Figure 3.5. Heg-/- Map3k3+/- hearts exhibit myocardial thinning at E12.5.

Figure 3.5. Heg-/- Map3k3+/- hearts exhibit myocardial thinning at E12.5. (A-D)
Heg-/- Map3k3+/- hearts (C-D) exhibit myocardial thinning relative to littermate controls
(A-B). B and D show higher magnification image of ventricular wall from A and C,
respectively. Scale bars are 100µm in A, C, and 50µm in B, D.
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Figure 3.6. Cardiac function is normal in E13.5 Heg-/- Map3k3+/- embryos.

Figure 3.6. Cardiac function is normal in E13.5 Heg-/- Map3k3+/- embryos.
Fractional shortening was measured on E13.5 embryos by echocardiography. Dots show
fractional shortening for individual embryo; graph lines show mean +/- sem for each
genotype. No significant changes were observed between the genotypes.
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Table 3.5. Survival of Tie2Cre Heg-/- Map3k3fl/+ mice.

Age
E14.5
P1

Cross: Heg-/- X Heg+/- Map3k3+/Tie2Cre
Tie2Cre
Heg+/Heg+/+/Heg
Heg-/Map3k3fl/+ Map3k3fl/+
fl/+
Map3k3
Map3k3fl/+
15
20
18
2
17
14
21
0

84

Total

P-value

55
52

0.003
<0.001

Table 3.6. Survival of Nfatc1Cre Heg-/- Map3k3fl/+ mice.

Age
E14.5
P1

Cross: Heg-/- X Heg+/- Map3k3+/Nfatc1Cre
Nfatc1Cre
Heg+/Heg+/+/Heg
Heg-/Map3k3fl/+ Map3k3fl/+
fl/+
Map3k3
Map3k3fl/+
9
7
10
4
12
14
20
6
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Total

P-value

30
52

0.423
0.052

Chapter 4: Conclusions and Future Directions

Summary
ATOH8 is a highly conserved bHLH transcription factor in vertebrates whose in
vivo role is largely undefined. In Chapter 2, I utilized a combination of zebrafish and
mouse models to characterize the requirements and functions of ATOH8. Through
morpholino studies in the zebrafish, I identified a requirement for atoh8 in the developing
zebrafish in regulating heart looping and swimbladder inflation. I further demonstrated
that atoh8 specifically interacts with gata4 and zfpm1 (encoding Fog1) in zebrafish heart
development. These results, combined with co-immunoprecipitation experiments
showing that murine ATOH8 physically interacts with murine FOG2, suggest that Atoh8
functions as a co-factor with the Gata4-Fog1 complex in zebrafish. However, multiple
Atoh8 mutant mouse models failed to exhibit any overt phenotype, in contrast to the
zebrafish. Partial postnatal lethality was observed in Gata4 and Atoh8 compound
mutants, suggesting that a weak genetic interaction may exist in the mouse, but to a
much-reduced extent relative to the zebrafish.
Prior work in the Kahn lab had identified the transmembrane protein HEG and the
adaptor protein CCM2L as required endocardial factors for proper generation of FGF
growth signals for the myocardium. How HEG and CCM2L regulate growth factor
production, however, had remained unclear. In Chapter 3, I identify MEKK3 as a likely
intermediary between HEG-CCM2L and growth factor production. I show that MEKK3
is capable of physically interacting with CCM2L and is required for CCM2L regulation
of FGF production in vitro. I further show that endocardial MEKK3 is required for
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myocardial proliferation, linking MEKK3 to endocardial growth factor signaling. I also
identify genetic interaction between Heg and Map3k3 (encoding MEKK3) in compound
mutant mice, further linking MEKK3 to the HEG-CCM complex in vivo. It remains to be
determined which growth signals are specifically disrupted in MEKK3 endocardial
mutants, what signals activate MEKK3 in the endocardium, and what pathways are
activated downstream of MEKK3 within the endocardium.

Future Directions: Atoh8
My studies on Atoh8 in murine development have definitively shown that Atoh8 is
not required for survival in developing mammals. Furthermore, although we do see weak
genetic interaction between the Atoh8 and Gata4 in the mouse, the phenotypic penetrance
of this interaction is very weak and I was unable to identify a clear cause of death in these
animals. Given that the Kahn lab focuses on mammalian cardiovascular development, it
is unlikely that we will continue to study Atoh8. However, I have identified two potential
future directions that may be of interest to other groups: 1) determining the mechanism
through which zebrafish atoh8 regulates cardiac development, and 2) possible functions
of Atoh8 in adult mammals.

The role of atoh8 in the zebrafish heart
My morpholino gene suppression studies clearly show that zebrafish heart looping
is dependent on Atoh8. I did not, however, identify molecular targets or pathways that
were disrupted in the morphant hearts. Heart looping defects have been linked to
multiple causes, including disruption of cardiac transcription factors (23,34,61,63,90),
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cardiac ion channels (91) and cardiac structural proteins (92). Given the robust synergy
we observe between Atoh8 and Gata4-Fog1 (Figure 2.3), there is likely a shared
mechanism between Atoh8 and these other genes in regulating heart looping.
Unfortunately, the studies to date in the zebrafish have not identified the targets of Gata4
(23) or Fog1 (34) in heart development, so there are no clear candidates. I therefore
propose examining the expression pattern of multiple developmental cardiac transcription
factors such as hand2, tbx5a, mef2c, gata5 and nkx2.5 by in situ hybridization in order to
determine if the specification of cardiomyocyte progenitors is preserved in atoh8, gata4,
and zfpm1 (Fog1) morphant embryos. I would propose further examination of the
expression of cardiac structural proteins such as cardiac actin and myosin genes to
determine whether proper development from progenitor to differentiated cardiomyocyte
is preserved. Given the lack of cardiac defects in Atoh8 mutant mice, it is unlikely that
these processes are conserved into mammals. However, these studies may reveal how
these factors contribute to heart looping and also may provide insight into how Atoh8,
Gata4, and Fog1 interact.

A possible role for Atoh8 in the adult iron metabolism
Although my studies showed that Atoh8 is not required for development and
survival, the high degree of conservation in ATOH8 sequence suggests evolutionary
pressure to preserve this protein and argues for some role for Atoh8 in mammals. Given
the lack of a requirement for Atoh8 in the embryo, it is plausible to infer that the
requirement for Atoh8 may be limited to the adult animal. Such requirements may be
difficult to observe in adult mice in the laboratory setting, particularly if Atoh8 is required
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in stress responses that a laboratory mouse may be unlikely to encounter. Based on my
work here and previously reported studies on Atoh8, I propose studying the potential
Atoh8 function in the regulation of iron metabolism in the adult liver.
Iron metabolism is regulated by multiple inputs, such as hepatic and circulating
iron levels, erythropoietic activity, and inflammation (93). In the liver, excess iron levels
are detected by an unknown sensor, which increases hepatic production of BMP6 (94).
BMP6 increases production of hepcidin, a regulatory protein that inhibits iron absorption
and iron export from the intestine and promotes sequestration of iron within
reticuloendothelial macrophages (93). Atoh8 has been shown to be upregulated in the
mouse liver following excess iron accumulation secondary to either dietary iron overload
or genetic deletion of hepcidin (95), indicating that Atoh8 may be part of the hepatic
response program to iron overload. Hepatic Atoh8 expression is also dependent on
BMP6-Smad4 signaling (95), suggesting that Atoh8 may be a direct target of this
signaling pathway. The mutant mice models we have generated for the Atoh8 project are
ideally suited for testing the requirement for ATOH8 in iron metabolism. I propose
examining the hepatic and circulating iron levels in adult Atoh8Δex1/Δex1 mice vs. control
littermates, on both a normal chow diet and an iron-enriched diet. If differences in iron
levels are observed in ATOH8-deficient animals, I propose examining the levels of
hepcidin and BMP6 to attempt to determine the mechanism by which ATOH8 affects
iron regulation. Intriguingly, a previous report identified GATA4 as a transcriptional
regulator of hepcidin (96); it is possible that the genetic and physical interactions I have
identified between ATOH8 and GATA4 in my work may be applicable in the context of
iron regulation.
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Future Directions: MEKK3
Our studies here have clearly shown that MEKK3 can interact with CCM2L and
regulate its function, and have also demonstrated that MEKK3 has a required role in the
endocardium that is very similar to the role of HEG and CCM2L in this tissue. Future
studies are now needed to further characterize the defects in Nfatc1Cre Map3k3fl/- mice, to
identify the factors upstream and downstream of MEKK3 in the endocardium, and to
investigate the role of other CCM proteins in the endocardium in development.

Characterizing the defect in Nfatc1Cre Map3k3fl/- mice
My experiments with the Nfatc1Cre Map3k3fl/- mice demonstrate that embryonic
lethality at E11.5 and severe myocardial thinning result from endocardial loss of
MEKK3. This phenotype is remarkably similar to the phenotype previously reported by
our lab in Heg-/- Ccm2l-/- embryos (58). Future experiments are needed to fully
characterize the Nfatc1Cre Map3k3fl/- phenotype to determine why endocardial loss of this
protein results in a myocardial defect. First, we need to determine why there is a
decrease in myocardial tissue—is this a decrease in proliferation, or an increase in
apoptosis? We will use bromodeoxyuridine (Brdu) pulse labeling and TUNEL staining
to determine the respective rate of proliferation and apoptosis in the endocardium and
myocardium of Nfatc1Cre Map3k3fl/- hearts. Preliminary immunostaining suggests that
proliferation is reduced within the myocardium of these animals with no changes in
endocardial proliferation or in apoptosis in either tissue (data not shown), which would
agree with the reported result in Heg-/- Ccm2l-/- embryos. Additional analysis is needed
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to quantify this proliferative change to confirm that there is a significant change in
Nfatc1Cre Map3k3fl/- hearts.
Following my studies on proliferation and apoptosis, I propose to examine how
loss of endocardial MEKK3 leads to myocardial defects. Given the physical separation
between the endocardium and myocardium at E10.5-11.5, it is reasonable to conclude
that there is a deficiency in a secreted endocardial factor. In the study of Heg-/- Ccm2l-/embryos, the decreased myocardial growth was attributed to a decrease in endocardial
FGF16 transcription (58), which had previously been shown to be required for
myocardial growth (45,59). It is therefore reasonable to start with FGF16 and the related
factors FGF9 and FGF20 as initial candidates. However, myocardial growth has been
shown to be dependent on multiple growth factor signals in addition to FGFs, such as
neuregulin (43) and Notch (97). I would therefore like to do transcriptional profiling of
whole E10.5 Nfatc1Cre Map3k3fl/- hearts to screen for changes in multiple signaling
pathways. If I am able to identify a signal as a plausible cause for the defects in Nfatc1Cre
Map3k3fl/- hearts, I will attempt to rescue the defect using heart explant cultures. In these
experiments, explanted hearts are cultured with replacement cytokines to rescue a
proliferation defect; this technique has previously been used to rescue hearts deficient in
FGFs (98) or neuregulin (97) to link proliferation specifically to deficits in these
endocardial growth factors.

Identifying the pathways downstream of MEKK3
MEKK3 is a MAPK kinase kinase kinase and has no known transcriptional
activity; it is likely that there are downstream targets of MEKK3 within the enodcardial
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cell that convey a signal that ultimately promotes increased transcription of growth factor
genes. Although the in vivo endothelial targets of MEKK3 have not been identified,
MEKK3 has been shown to be upstream of the MAPK kinases ERK5 and p38 in cultured
endothelial cells (99). In immune cells, where it has been studied more extensively,
MEKK3 has been shown to have additional roles as an upstream activator of the MAPK
kinase JNK and also as an activator of NF-ΚB pathway (100). These pathways are our
best candidates for possible downstream targets of MEKK3 in the endocardium. We
propose three approaches to identifying which target pathway is critical in these cells.
First, we will examine the phosphorylation of MAPK and NF-ΚB pathway components
in E10.5 Nfatc1Cre Map3k3fl/- hearts to screen for decreased activation of these pathways
with endocardial loss of MEKK3. While this approach allows me to look directly at the
in vivo situation, it is potentially complicated by the small number of cells in an E10.5
heart, which would limit omy source material, and by the presence of non-endocardial
cells (primarily myocardium), which may have phosphorylated MAPK proteins and mask
changes in the endocardium. To address the latter concern, I could attempt to sort
endocardium from these hearts to isolate a pure population, although I would still be
limited by the number of endocardial cells.
In addition to investigating phosphorylation in vivo, I will also use our adenoviralCCM2L HMVEC expression system (Figure 3.2) to identify possible MEKK3 targets. In
this system, overexpression of CCM2L increases FGF16 transcription. Suppression of
MEKK3 with siRNA inhibits this increase, indicating that CCM2L is likely acting
through MEKK3 and suggesting that this cell culture system may be a somewhat similar
model of the in vivo pathway in the endocardium. I will use siRNA against potential
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targets of MEKK3 in the endocardium in order to identify which proteins are required for
this CCM2L-induced upregulation of FGF16 levels.
Finally, I can ablate candidate genes in the endocardium using the Nfatc1Cre allele
and screen for phenotypes similar to the Nfatc1Cre Map3k3fl/- mouse. This approach is the
best tool for confirming that the candidate is truly operating in the same path as MEKK3;
however, the large number of possible candidates precludes pursuing this approach on a
large scale and I will therefore limit this approach to our most likely candidates. At this
point, I plan to pursue this approach with the MAPK kinase ERK5; I suspect ERK5
because it has been shown regulated by MEKK3 in the endothelium (99), and because
endothelial-specific ERK5 mutants are highly similar to MEKK3 mutants (85,101). If
my other approaches identify other MAPK and NF-ΚB pathways as being better
candidates than ERK5, we will make endocardial deletions of those genes.

Identifying the upstream activator of MEKK3
In addition to identifying the downstream targets of MEKK3 in the endocardium,
I would like to identify potential upstream signals that activate MEKK3, presumably
through an activating phosphorylation of MEKK3. Although HEG and the CCM proteins
genetically and/or physically interact with MEKK3, none of these proteins have intrinsic
kinase activity and therefore would be unable to directly activate MEKK3. In order to
identify potential activators of MEKK3, I will attempt to detect proteins that physically
interact with MEKK3 and the HEG/CCM complex, which I hypothesize may interact
with MEKK3 in the endocardium. I will create a lentiviral construct expressing FLAGHA-HEG or FLAG-HA-MEKK3 in a doxycycline-inducible manner. I will use this
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lentivirus to express tagged proteins in endothelial cells such as HMVECs, and then
titrate the level of expression to endogenous levels via the doxycycline-inducible system.
I will then immunoprecipitate the tagged proteins via their double epitope tags, and
perform mass spectrometry to identify binding partners of HEG and MEKK3.
As an alternative to the traditional immunoprecipitate mass spectrometry
approach, I am also using a recently reported biotin-labeling strategy to identify HEG and
MEKK3 interactors (102). In this approach, a mutated promiscuous biotin ligase is fused
to the protein of interest. The biotin ligase biotinylates other proteins in the vicinity of
the fusion protein; interacting proteins should be enriched when biotinylated proteins are
immunoprecipitated from the cell lysate. This approach is particularly attractive for
identifying HEG interactors, as the lysis conditions necessary to liberate HEG from the
cell membrane may disrupt protein-protein interactions, whereas a biotin-tag should be
permanent even if interactions are disrupted by lysis. However, there may be more
background noise with this approach, as non-interacting proteins in the same subcellular
domain as HEG or MEKK3 may also be labeled.

Determining the endocardial functions of CCM proteins
My studies with the Nfatc1Cre Map3k3fl/- mouse revealed a clear requirement for
MEKK3 in the endocardium that had been previously been hidden by the early
embryonic death imposed by vascular defects in constitutive and endothelial (Tie2Cre)
deletions of this gene. I would like to pursue a similar approach with CCM1 and CCM2.
Global and endothelial-specific mutants of CCM1 and CCM2 are lethal at E9.5 due to
defects in development of the branchial arch arteries (54,55). This results in a failure to
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connect the heart outflow tract with the descending aorta, which prevents effective
circulation. My lineage trace experiments show that Nfatc1Cre expression is not present
in the branchial arch arteries (Figure 3.3), indicating that deletion of CCM1 or CCM2
with this Cre allele should bypass this early lethal vascular defect. I will generate
Nfatc1Cre Krit1fl/fl and Nfatc1Cre Ccm2fl/fl to delete CCM1 and CCM2, respectively, in the
endocardium. Preliminary results showing an absence of viable Nfatc1Cre Krit1fl/fl
animals at birth (Table 3.3) indicate that CCM1 is required at some point in the
endocardium in embryogenesis; timed matings are needed to determine when and why
these animals die. I will pursue similar crosses with the Ccm2fl allele to determine the
requirement for CCM2. It is possible that CCM2 may be redundant with its paralogue
CCM2L, which is expressed in the embryonic endocardium (58). To account for this
possibility, I will also examine Nfatc1Cre Ccm2fl/fl Ccm2l-/- double mutant animals. If
MEKK3 interacts with CCM1 or CCM2 in the endocardium, it is possible that the
endocardial deletions of CCM1 or CCM2 will phenocopy endocardial deletion of
MEKK3. Alternatively, I may see other defects within the endocardium, or lethal defects
in the development of the coronary endothelium that is arises from endocardium in later
embryogenesis (Figure 3.3).

Concluding remarks
Our studies of ATOH8 clearly define the requirements for ATOH8 between
different vertebrate species. While there is a requirement for atoh8 in the developing
zebrafish heart, our Atoh8 null mice definitively demonstrate that this requirement is not
preserved in mammalian development. In a similar manner, the robust genetic interaction
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we observe between Atoh8 and Gata/Fog proteins in the zebrafish development is much
reduced in the mouse. Further studies will be needed to determine if and where ATOH8
may function in the adult mammal, and to determine whether ATOH8 interacts with
GATA or FOG factors in these processes outside of development.
Our studies of MEKK3 indicate that this kinase has a critical role in the
endocardium to facilitate myocardial growth, likely by promoting growth factor
production. This finding provides a mechanism to explain the phenotype that was
observed in HEG-CCM2L double mutant mice, and identifies a role for MEKK3 in the
endocardium that had previously been masked by the early lethal vascular defects of prior
deletions of this gene. Future studies are needed to define the upstream activators and
downstream targets of MEKK3 within the endocardium, and to further define the
functions and interactions of the HEG-CCM-MEKK3 complex within the endocardium
and within the remainder of the endothelium.
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